AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesTechnology, Industry, Agriculture
Urinary Bladder NeoplasmsUrinary BladderCarcinoma, Transitional CellUrinary Bladder DiseasesUrinary Bladder CalculiUrotheliumUrinary Bladder, OveractiveCystitisUrinary Bladder Neck ObstructionUrinary Bladder, NeurogenicButylhydroxybutylnitrosamineUrinationUrinary TractUrinary Tract InfectionsCystoscopyUrinary IncontinenceUrinary CatheterizationMuscle, SmoothUrinary RetentionCystectomyUrodynamicsBufo marinusAdministration, IntravesicalNeoplasmsUrineHematuriaUrinary CalculiMuscle ContractionUrinary Bladder FistulaPancreatic NeoplasmsVitaminsRecurrencePharmaceutical PreparationsNeoplasm Recurrence, LocalDrug-Related Side Effects and Adverse Reactions
Urinary Bladder Neoplasms
Tumors or cancer of the URINARY BLADDER.
Urinary Bladder
A musculomembranous sac along the URINARY TRACT. URINE flows from the KIDNEYS into the bladder via the ureters (URETER), and is held there until URINATION.
Carcinoma, Transitional Cell
A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.
Urinary Bladder Diseases
Pathological processes of the URINARY BLADDER.
Urinary Bladder Calculi
Stones in the URINARY BLADDER; also known as vesical calculi, bladder stones, or cystoliths.
Urothelium
The epithelial lining of the URINARY TRACT.
Urinary Bladder, Overactive
Symptom of overactive detrusor muscle of the URINARY BLADDER that contracts with abnormally high frequency and urgency. Overactive bladder is characterized by the frequent feeling of needing to urinate during the day, during the night, or both. URINARY INCONTINENCE may or may not be present.
Cystitis
Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain.
Urinary Bladder Neck Obstruction
Blocked urine flow through the bladder neck, the narrow internal urethral opening at the base of the URINARY BLADDER. Narrowing or strictures of the URETHRA can be congenital or acquired. It is often observed in males with enlarged PROSTATE glands.
Urinary Bladder, Neurogenic
Dysfunction of the URINARY BLADDER due to disease of the central or peripheral nervous system pathways involved in the control of URINATION. This is often associated with SPINAL CORD DISEASES, but may also be caused by BRAIN DISEASES or PERIPHERAL NERVE DISEASES.
Butylhydroxybutylnitrosamine
A substituted carcinogenic nitrosamine.
Urination
Discharge of URINE, liquid waste processed by the KIDNEY, from the body.
Urinary Tract
The duct which coveys URINE from the pelvis of the KIDNEY through the URETERS, BLADDER, and URETHRA.
Urinary Tract Infections
Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA.
Cystoscopy
Endoscopic examination, therapy or surgery of the urinary bladder.
Urinary Incontinence
Involuntary loss of URINE, such as leaking of urine. It is a symptom of various underlying pathological processes. Major types of incontinence include URINARY URGE INCONTINENCE and URINARY STRESS INCONTINENCE.
Urinary Catheterization
Passage of a CATHETER into the URINARY BLADDER or kidney.
Muscle, Smooth
Unstriated and unstriped muscle, one of the muscles of the internal organs, blood vessels, hair follicles, etc. Contractile elements are elongated, usually spindle-shaped cells with centrally located nuclei. Smooth muscle fibers are bound together into sheets or bundles by reticular fibers and frequently elastic nets are also abundant. (From Stedman, 25th ed)
Urinary Retention
Inability to empty the URINARY BLADDER with voiding (URINATION).
Cystectomy
Used for excision of the urinary bladder.
Urodynamics
The mechanical laws of fluid dynamics as they apply to urine transport.
Bufo marinus
A species of the true toads, Bufonidae, becoming fairly common in the southern United States and almost pantropical. The secretions from the skin glands of this species are very toxic to animals.
Administration, Intravesical
The instillation or other administration of drugs into the bladder, usually to treat local disease, including neoplasms.
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Urine
Liquid by-product of excretion produced in the kidneys, temporarily stored in the bladder until discharge through the URETHRA.
Hematuria
Presence of blood in the urine.
Urinary Calculi
Low-density crystals or stones in any part of the URINARY TRACT. Their chemical compositions often include CALCIUM OXALATE, magnesium ammonium phosphate (struvite), CYSTINE, or URIC ACID.
Muscle Contraction
A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.
Urinary Bladder Fistula
An abnormal passage in the URINARY BLADDER or between the bladder and any surrounding organ.
Pancreatic Neoplasms
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
Vitamins
Organic substances that are required in small amounts for maintenance and growth, but which cannot be manufactured by the human body.
Recurrence
The return of a sign, symptom, or disease after a remission.
Pharmaceutical Preparations
Drugs intended for human or veterinary use, presented in their finished dosage form. Included here are materials used in the preparation and/or formulation of the finished dosage form.
Neoplasm Recurrence, Local
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
Drug-Related Side Effects and Adverse Reactions
Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.

Long-term transplantability and morphological stability of three experimentally induced urinary bladder carcinomas in rats. (1/4713)

Three transitional cell carcinomas induced in Fischer 344 rats by a methylcholanthrene pellet or a foreign body inserted locally into the bladder have been serially transplanted in the syngeneic strain for up to 6.5 years. There have been no changes in the individual morphological characteristics of the tumors during this time. Cells cultured in vitro for varying numbers of passages reproduce regularly the morphology of each tumor when they are injected back into the animals and results from a microcytotoxicity assay for cellular immunity indicate that they retain a common, bladder tumor-specific antigen. These tumors are useful for research in turmo biology and are offered to other scientists seeking transplantable carcinomas for experimentation.  (+info)

Natural history of papillary lesions of the urinary bladder in schistosomiasis. (2/4713)

Variable epithelial hyperplasia was observed in urinary bladder of nine capuchin monkeys (Cebus apella) when examined at cystotomy 94 to 164 weeks after infection with Schistosoma haematobium. These hosts were followed for 24 to 136 weeks postcystotomy to determine the status of bladder lesions in relation to duration of infection and to ascertain whether lesion samples removed at cystotomy reestablished themselves in autologous and heterologous transfers. There was involution of urothelial hyperplasia in eight of nine animals and no evidence for establishment of transplanted bladder lesions.  (+info)

Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer. (3/4713)

The evolution of alterations on chromosome 9, including the putative tumor suppressor genes mapped to the 9p21-22 region (the MTS genes), was studied in relation to the progression of human urinary bladder neoplasia by using whole organ superimposed histologic and genetic mapping in cystectomy specimens and was verified in urinary bladder tumors of various pathogenetic subsets with longterm follow-up. The applicability of chromosome 9 allelic losses as non-invasive markers of urothelial neoplasia was tested on voided urine and/or bladder washings of patients with urinary bladder cancer. Although sequential multiple hits in the MTS locus were documented in the development of intraurothelial precursor lesions, the MTS genes do not seem to represent a major target for p21-23 deletions in bladder cancer. Two additional tumor suppressor genes involved in bladder neoplasia located distally and proximally to the MTS locus within p22-23 and p11-13 regions respectively were identified. Several distinct putative tumor suppressor gene loci within the q12-13, q21-22, and q34 regions were identified on the q arm. In particular, the pericentromeric q12-13 area may contain the critical tumor suppressor gene or genes for the development of early urothelial neoplasia. Allelic losses of chromosome 9 were associated with expansion of the abnormal urothelial clone which frequently involved large areas of urinary bladder mucosa. These losses could be found in a high proportion of urothelial tumors and in voided urine or bladder washing samples of nearly all patients with urinary bladder carcinoma.  (+info)

Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer. (4/4713)

Recent studies have shown that patients whose bladder cancer exhibit overexpression of RB protein as measured by immunohistochemical analysis do equally poorly as those with loss of RB function. We hypothesized that loss of p16 protein function could be related to RB overexpression, since p16 can induce transcriptional downregulation of RB and its loss may lead to aberrant RB regulation. Conversely, loss of RB function has been associated with high p16 protein expression in several other tumor types. In the present study RB negative bladder tumors also exhibited strong nuclear p16 staining while each tumor with strong, homogeneous RB nuclear staining were p16 negative, supporting our hypothesis. To expand on these immunohistochemical studies additional cases were selected in which the status of the p16 encoding gene had been determined at the molecular level. Absent p16 and high RB protein expression was found in the tumors having loss of heterozygosity within 9p21 and a structural change (mutation or deletion) of the remaining p16 encoding gene allele, confirming the staining results. These results strongly support the hypothesis that the RB nuclear overexpression recently associated with poor prognosis in bladder cancer is also associated with loss of p16 function and implies that loss of p16 function could be equally deleterious as RB loss in bladder and likely other cancers.  (+info)

Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop. (5/4713)

The Mdm2 protein is frequently overexpressed in human non-seminomatous germ cell tumours and transitional carcinoma of the bladder where it may contribute to tolerance of wtp53. Mdm2 forms an autoregulatory feedback loop with p53; the Mdm2 gene is responsive to transactivation by p53 and once synthesized the Mdm2 protein terminates the p53 response. We show here that the topoisomerase poison etoposide, like ultra violet irradiation, inhibits Mdm2 synthesis. Cytotoxic concentrations of etoposide (IC90 for > 3 h) result in inhibition of Mdm2 induction at both the RNA and protein level. Rapid apoptosis ensues. Global transcription is not inhibited: p21waf-1/cip1 and GADD45 expression increase in a dose dependent manner. Inhibition of Mdm2 synthesis depends on the continuous presence of etoposide, suggesting the DNA damage may prevent transcription. Downregulation of Mdm2 transcript occurs in cells expressing HPV16-E6 suggesting that inhibition of Mdm2 transcription is p53-independent. When cells are -treated with a pulse (1 h) of etoposide and reincubated in drug free medium, Mdm2 synthesis commences immediately after damage is repaired (3 h) and the p53 response is attenuated. Induction of apoptosis and loss of clonogenicity are 3-5-fold lower under pulse treatment conditions. This is the first observation of inhibition of Mdm2 transcription following treatment with topoisomerase (topo II) poisons, a feature that may be useful in tumour types where p53 is tolerated by overexpression of Mdm2.  (+info)

Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. (6/4713)

Interleukin (IL)-10 is a potent immunosuppressive cytokine that has been found to be present at the tumor site in a wide variety of human cancers, including transitional cell carcinoma of the bladder. Using a murine bladder tumor (MB49), which we show to express the male transplantation antigen (HY), we tested the hypothesis that IL-10 at the tumor site can block the generation of a tumor-specific type 1 immune response. We show that, despite its expression of HY, MB49 fails to prime for an HY-specific type 1 (IFN-gamma) response in normal female mice. Although MB49 does not constitutively produce IL-10, our data support a model whereby MB49 induces infiltrating cells to produce IL-10. This feature rendered the IL-10 knockout (KO) mouse, whose infiltrating cells are incapable of IL-10 production, a suitable model in which to study MB49 in the absence of IL-10. When injected into IL-10 KO mice, MB49 does prime for an HY-specific, type 1 immune response. Furthermore, IL-10 KO mice show prolonged survival and an increased capacity to reject tumors as compared with normal mice. We also tested the ability of tumor-induced IL-10 to inhibit immunization to a non-tumor antigen present at the tumor site. When vaccinia virus encoding beta-galactosidase (beta-gal) is injected into the tumors of normal mice, no beta-gal-specific IFN-gamma response is mounted. However, when this same viral construct is injected into the tumors of IL-10 KO mice, it produces a strong beta-gal-specific, IFN-gamma response. These studies demonstrate that tumor-induced IL-10 can block the generation of a tumor-specific type 1 immune response as well as subvert attempts to elicit a type 1 immune response to a non-tumor antigen at the tumor site.  (+info)

Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. (7/4713)

Epidermal growth factor receptor (EGFR) regulates the growth and progression of human transitional cell carcinoma (TCC) of the bladder. We have shown that therapy targeting EGFR inhibited the growth of human TCC established orthotopically in nude mice. The purpose of this study was to evaluate whether EGFR-directed therapy affects angiogenesis associated with the growth and metastasis of human TCC. We determined the cytostatic effect and the effect on production of angiogenic factors after in vitro treatment of the human TCC cell line 253J B-V with MAb C225, a chimerized monoclonal anti-EGFR antibody. The 253J B-V cells were implanted orthotopically into athymic nude mice, and established tumors (4 weeks) were treated with i.p. MAb C225. Expression of the angiogenic factors vascular endothelial growth factor (VEGF), interleukin-8 (IL-8), and basic fibroblast growth factor (bFGF) was evaluated by immunohistochemistry and in situ mRNA hybridization analyses and correlated with microvessel density evaluated after immunohistochemical staining with anti-CD31. In vitro treatment with MAb C225 inhibited mRNA and protein production of VEGF, IL-8, and bFGF by 253J B-V cells in a dose-dependent manner. MAb C225 therapy of nude mice with established TCCs growing orthotopically resulted in inhibition of growth and metastasis compared with controls (P <0.0005). VEGF, IL-8, and bFGF expression was significantly lower in treated tumors than in controls. The down-regulation of these angiogenic factors preceded the involution of blood vessels. These studies indicate that therapy with anti-EGFR MAb C225 has a significant antitumor effect mediated, in part, by inhibition of angiogenesis.  (+info)

Vaginal epithelioid angiosarcoma. (8/4713)

A case of epithelioid angiosarcoma of the vagina is described. Only five cases of angiosarcoma at this site have been reported, three of which followed radiotherapy for other gynaecological malignancies. None is described as an epithelioid angiosarcoma, an unusual and recently described variant which is readily confused with carcinoma. This is thought to be the first reported epithelioid angiosarcoma at this site and highlights the difficulties in diagnosis.  (+info)

Mutation Induction by Ionizing Radiation in Three Human Bladder Tumour Cell Lines. - Lancaster EPrintsMutation Induction by Ionizing Radiation in Three Human Bladder Tumour Cell Lines. - Lancaster EPrints
Mutation induction at the hypoxanthine-guanine phosphoribosyl transferase (hprt) locus has been studied in three human bladder tumour cell lines of varying radiosensitivity. U1-S40b, a radiosensitive mutant clone of MGH-U1, has been previously reported to show no difference in split-dose recovery or low dose-rate sparing, but to have an impaired repair fidelity when compared to its parent line. In this paper we have shown that U1-S40b is less mutable at the hprt locus at a similar level of survival. This may represent an increased incidence of severe or non-repairable lesions, making hprt- mutants poorly recoverable in U1-S40b when compared to MGH-U1. No difference was seen in mutation induction between MGH-U1 and RT112, another human bladder tumour cell line of similar radiosensitivity to MGH-U1.. ...
https://eprints.lancs.ac.uk/id/eprint/8760/?template=browse
Non Muscle Invasive Bladder Cancer Pipeline, Clinical Trials and Emerging Therapy Assessment by DelveInsight - Jaipur HeraldNon Muscle Invasive Bladder Cancer Pipeline, Clinical Trials and Emerging Therapy Assessment by DelveInsight - Jaipur Herald
DelveInsight has launched a new report on Non Muscle Invasive Bladder Cancer Pipeline. Non-muscle invasive bladder cancer (NMIBC) formerly known as superficial bladder cancer, is a common, heterogeneous disease associated with high rates of recurrence that often requires lifelong surveillance. The cancer is found in the tissue that lines the inner surface of the bladder wherein the bladder muscle is not involved.. Request for free sample copy- https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-pipeline-insight Non Muscle Invasive Bladder Cancer Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of Non Muscle Invasive Bladder Cancer Pipeline products with detailed clinical profiles, key cross -competition, launch date along with product development activities.. Non Muscle Invasive Bladder Cancer Pipeline. The high-grade NMIBC pipeline possesses potential drugs in mid and late stage ...
http://www.jaipurherald.in/story/115243/non-muscle-invasive-bladder-cancer-pipeline-clinical-trials-and-emerging-therapy-assessment-by-delveinsight.html
Cytokine production by the human bladder carcinoma cell line T...Cytokine production by the human bladder carcinoma cell line T...
Cytokine production by the human bladder carcinoma cell line T24 in the presence of bacillus Calmette-Guerin (BCG).: The study was initiated as an in vitro appr
https://www.mysciencework.com/publication/show/cytokine-production-human-bladder-carcinoma-cell-line-t24-presence-bacillus-calmette-guerin-bcg-9facf2dd
Metastatic bladder cancer: Advances in treatment<...
TY - JOUR. T1 - Metastatic bladder cancer. T2 - Advances in treatment. AU - Stadler, W. M.. AU - Kuzel, T. M.. AU - Raghavan, D.. AU - Levine, E.. AU - Vogelzang, N. J.. AU - Roth, B.. AU - Dorr, F. A.. N1 - Funding Information: Acknowledgements---Studies were supported by research grants from Eli Lilly and Company.. PY - 1997/1. Y1 - 1997/1. N2 - At present, a combination of cisplatin, methotrexate, vinblastine and doxorubicin is the most widely used chemotherapy for metastatic bladder cancer. However, long-term follow up shows that this combination may have little effect on survival. In addition, this regimen is toxic. New agents are needed which combine efficacy with good safety profiles. Agents which have been investigated include gallium nitrate, interferon-α and paclitaxel both as single agents and in combination with established cytotoxic drugs. A number of studies have been conducted in bladder cancer with the novel nucleoside analogue, gemcitabine. Response rates of up to 33% have been ...
https://www.scholars.northwestern.edu/en/publications/metastatic-bladder-cancer-advances-in-treatment
Intravesical Gemcitabine and Docetaxel for BCG na ve Non-muscle Invasive Bladder Cancer | Clinical Research Trial Listing (...Intravesical Gemcitabine and Docetaxel for BCG na ve Non-muscle Invasive Bladder Cancer | Clinical Research Trial Listing (...
Clinical trial for Urothelial Carcinoma Bladder | bladder cancer | bladder disorder | transitional cell carcinoma of bladder | Urothelial Cancer | carcinoma of the bladder | Bladder Carcinoma | bladder tumor | urinary tract neoplasm | Urologic Cancer | Transitional Cell Carcinoma of the Bladder | Bladder Disorders , Intravesical Gemcitabine and Docetaxel for BCG na ve Non-muscle Invasive Bladder Cancer
https://www.centerwatch.com/clinical-trials/listings/249778/intravesical-gemcitabine-and-docetaxel-for-bcg-na-ve-non-muscle-invasive-bladder-cancer/?&radius=50&query=invasive%20bladder%20cancer&page=5&rnk=15
ICUD-EAU international consultation on bladder cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder<...
TY - JOUR. T1 - ICUD-EAU international consultation on bladder cancer 2012. T2 - Non-muscle-invasive urothelial carcinoma of the bladder. AU - Burger, Maximilian. AU - Oosterlinck, Willem. AU - Konety, Badrinath. AU - Chang, Sam. AU - Gudjonsson, Sigurdur. AU - Pruthi, Raj. AU - Soloway, Mark. AU - Solsona, Eduardo. AU - Sved, Paul. AU - Babjuk, Marko. AU - Brausi, Maurizio A.. AU - Cheng, Christopher. AU - Comperat, Eva. AU - Dinney, Colin. AU - Otto, Wolfgang. AU - Shah, Jay. AU - Thürof, Joachim. AU - Witjes, J. Alfred. PY - 2013/1. Y1 - 2013/1. N2 - Context: Our aim was to present a summary of the Second International Consultation on Bladder Cancer recommendations on the diagnosis and treatment options for non-muscle-invasive urothelial cancer of the bladder (NMIBC) using an evidence-based approach. Objective: To critically review the recent data on the management of NMIBC to arrive at a general consensus. Evidence acquisition: A detailed Medline analysis was performed for original articles ...
https://miami.pure.elsevier.com/en/publications/icud-eau-international-consultation-on-bladder-cancer-2012-non-mu
Commentary on Prognostic effect of carcinoma in situ in muscle-invasive urothelial carcinoma patients receiving neoadjuvant...
TY - JOUR. T1 - Commentary on Prognostic effect of carcinoma in situ in muscle-invasive urothelial carcinoma patients receiving neoadjuvant chemotherapy.. AU - Thomas, D. E.. AU - Kaimakliotis, H. Z.. AU - Rice, K. R.. AU - Pereira, J. A.. AU - Johnston, P.. AU - Moore, M. L.. AU - Reed, A.. AU - Cregar, D. M.. AU - Franklin, C.. AU - Loman, R. L.. AU - Koch, M. O.. AU - Bihrle, R.. AU - Foster, R. S.. AU - Masterson, T. A.. AU - Gardner, T. A.. AU - Sundaram, C. P.. AU - Powell, C. R.. AU - Beck, S. D.W.. AU - Grignon, D. J.. AU - Cheng, L.. AU - Albany, C.. AU - Hahn, N. M.. PY - 2018/7. Y1 - 2018/7. N2 - Background: Carcinoma in situ (CIS) is a poor prognostic finding in urothelial carcinoma. However, its significance in muscle-invasive urothelial carcinoma (MIUC) treated with neoadjuvant chemotherapy (NAC) is uncertain. We assessed the effect of CIS found in pretreatment transurethral resection of bladder tumor (TURBT) biopsies on the pathologic and clinical outcomes. Materials and ...
https://jhu.pure.elsevier.com/en/publications/commentary-on-prognostic-effect-of-carcinoma-in-situ-in-muscle-in
Bladder Cancer | DASPITEBladder Cancer | DASPITE
Treatment depends on the grade and extent of invasion of the bladder cancer. In most cases, an urgent transurethral resection of bladder tumour (TURBT) is carried out, and intravesical chemotherapy to reduce the risk of recurrence.. ​. Low grade, non-muscle invasive bladder cancer (Ta). TURBT + intravesical mitomycin C at the same time. Follow-up cystoscopy 3 months and then 12 months and discharge if no recurrence. If intermediate risk, follow-up cystoscopy at 3, 9, 18 months then yearly. If recurring ,12 months, give course of 6 doses intravesical mitomycin C. ​. High grade, non-muscle invasive bladder cancer (T1). TURBT. Either intravesical BCG immunotherapy or radical cystectomy. Cystectomy if poor response to ,2 sets BCG. Follow-up cystoscopy every 3 months for 2 years, then every 6 months for 2 years, then yearly. ​. Muscle invasive bladder cancer (T2-T4). Neoadjuvant chemotherapy. Radical cystectomy or radiotherapy. Follow-up: yearly imaging and monitoring of kidney function, ...
https://www.daspite.com/bladder-cancer
Antigen common to several species, recognized by a rat monoclonal antibody raised against syngeneic rat bladder tumor<...
TY - JOUR. T1 - Antigen common to several species, recognized by a rat monoclonal antibody raised against syngeneic rat bladder tumor. AU - Eto, Hiroshi. AU - Saya, Hideyuki. AU - Nakata, Motomi. AU - Mizoguchi, Akira. AU - Kamidono, Sadao. PY - 1989/9/15. Y1 - 1989/9/15. N2 - A rat monoclonal antibody (MAb) termed RS‐11 (Ig M) was obtained by syngeneic immunization with rat bladder tumor cells induced by N‐butyl, N‐hydroxybutylnitrosamine (BBN). immunocytochemical analysis showed that RS‐11 is also reactive with mouse, dog and human bladder tumor‐cell lines and some other human tumor‐cell lines but not myeloma or leukemia cells. Immunohistochemical examination of paraffin‐embedded tissues has shown that RS‐11 is reactive with mouse, rat, dog and human bladder tumors (5/5, 5/5, 1/1, 31/ 49) and some other tumors, but not with normal human uro‐thelium or normal rat tissues. The antigen is expressed on the majority of low‐grade or well‐differentiated tumors, but less on ...
https://keio.pure.elsevier.com/en/publications/antigen-common-to-several-species-recognized-by-a-rat-monoclonal-
ASCO 2021: Steps Toward a Bladder-Intact Cure for Muscle-Invasive Bladder CancerASCO 2021: Steps Toward a Bladder-Intact Cure for Muscle-Invasive Bladder Cancer
bladder-intact cure for muscle-invasive bladder cancer, Improving downstaging of bladder cancer, Improving systemic disease control in the neoadjuvant period of bladder cancer, Consolidating local tumor control of bladder cancer, Improving systemic disease control in the adjuvant period of bladder cancer, Pembrolizumab in combination with gemcitabine and concurrent hypofractionated radiation therapy as bladder sparing treatment for muscle-invasive bladder cancer, durvalumab plus tremelimumab with concurrent radiotherapy in patients with localized muscle-invasive bladder cancer treated with a selective bladder preservation approach: IMMUNOPRESERVE-SOGUG trial
https://www.urotoday.com/conference-highlights/asco-2021/asco-2021-bladder-cancer/130072-asco-2021-discussant-steps-toward-a-bladder-intact-cure-for-muscle-invasive-bladder-cancer.html
A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer - Full Text View ...A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer - Full Text View ...
Bladder cancer is the fifth most common cancer in the United States with an estimated 71,000 new cases and approximately 14,000 deaths in 2009. Bladder cancer is also the costliest to treat per patient of all cancers, with annual direct medical expenditures in excess of $3.7 billion in the United States. This is largely because approximately 70% of all new cases of bladder cancer present as non-muscle invasive bladder cancer (NMIBC), which tends to recur, requiring repeated interventions and long-term follow-up.. NMIBC tumors are usually treated by surgical resection and intravesical chemotherapy and immunotherapy. Immunotherapy usually consists of intravesical administration of Bacillus Calmette-Guerin (BCG). Recent studies suggest that BCG is superior in terms of efficacy and decreasing disease recurrence compared to other therapies. Although the mechanism of action for BCG therapy leading to clinical efficacy is unclear, macrophages, T lymphocytes and natural killer (NK) cells are implicated ...
https://clinicaltrials.gov/ct2/show/study/NCT01625260?show_desc=Y
Plus itPlus it
Gene expression profiling of bladder tumor cell lines and human bladder cancers. Isogenic T24T cells, bladder carcinoma-derived cell lines, primary human bladder carcinomas, and normal bladder tissues were profiled on HG-U133A GeneChip arrays (Affymetrix, Santa Clara, CA). For the previously described isogenic T24T cell pair containing vector or RhoGDI2 constructs ( 4), duplicate RNA samples were generated from independent cell cultures; RNA from the 41 human bladder cancer cell lines [acquired from American Type Culture Collection (Manassas, VA) or from Dr. Monica Liebert (M.D. Anderson Cancer Center, Houston, TX)] was generated from a single log-phase culture. Following approval of the University of Virginia Human Investigation Committee, 23 primary bladder cancer samples of varying pathologic stages and five samples of normal urothelium were obtained and evaluated by a genitourinary pathologist (H.F.F.). For the malignant samples, only areas containing ,80% cancer cells were processed for RNA ...
https://cancerres.aacrjournals.org/content/65/16/7320
E-GEOD-42089 - The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell cycle...
PURPOSE: Despite over 70,000 new cases of bladder cancer in the United States annually, patients with advanced disease have a poor prognosis due to limited treatment modalities. We evaluate the role of Aurora A, identified as an upregulated candidate molecule in bladder cancer, in regulating bladder tumor growth. EXPERIMENTAL DESIGN: Gene expression in human bladder cancer samples was evaluated using RNA microarray and reverse-transcriptase PCR. The specific Aurora kinase A inhibitor MLN8237 (Millennium) was used to determine effects on bladder cancer cell growth using in vitro and in vivo models using malignant T24 and UM-UC-3 and papilloma-derived RT4 bladder cells. RESULTS: Urothelial carcinoma upregulates a set of 13 mitotic spindle associated transcripts, as compared to normal urothelium, including MAD2L1 (7.6-fold), BUB1B (8.8-fold), Aurora kinases A (5.6-fold) and Aurora kinase B (6.2-fold). Application of MLN8237 (10nM-1µM) to the human bladder tumor cell lines T24 and UM-UC-3 induced dose
https://www.omicsdi.org/dataset/arrayexpress-repository/E-GEOD-42089
Daratumumab in Treating Patients With Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer | Clinical Research Trial...Daratumumab in Treating Patients With Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer | Clinical Research Trial...
Clinical trial for Renal Cell Carcinoma | urinary tract cancer | Bladder Urothelial Carcinoma | Transitional Cell Carcinoma of the Bladder | Metastatic Kidney Carcinoma | clear cell renal cell carcinoma | Malignant Adenoma | Stage IV Renal Cell Cancer AJCC v8 | Adenocarcinoma | transitional cell carcinoma of bladder | Malignant neoplasm of kidney | Renal Cancer | Urologic Cancer | Renal Cell Cancer | Malignant Neoplasms of Urinary Tract | Kidney Cancer | urinary tract neoplasm , Daratumumab in Treating Patients With Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer
https://www.centerwatch.com/clinical-trials/listings/205819/daratumumab-in-treating-patients-with-muscle-invasive-bladder-cancer-or-metastatic-kidney-cancer/?q=invasive+bladder+cancer&page=5&query=invasive%20bladder%20cancer&rnk=50
Immune Characterization of High-Grade Bladder Cancer - University of North Carolina at Chapel Hill
In the United States, urothelial carcinoma (UC) of the bladder is the fourth most common malignancy in men and ninth most common in women with 72,570 new cases and 15,210 deaths expected in 2013. Bladder cancer can be divided into low-grade and high-grade tumors. While patients with low-grade tumors uniformly have a good prognosis, those with high-grade tumors clinical outcome is much worse and much more varied (so called heterogeneous). To better understand the heterogeneity within high-grade bladder cancer we examined the expression patterns of genes within a large group of high-grade, muscle-invasive bladder tumors and found that there are two distinct classes of bladder tumors that can be distinguished by their gene expression patterns but not by other means such as histology. Because of their similarity to several of the expression subtypes of breast cancer we have named the basal and luminal and developed a gene expression classifier consisting of 47 genes (BASE47) that can accurately ...
https://uncch.pure.elsevier.com/en/projects/immune-characterization-of-high-grade-bladder-cancer
Management of Non-Muscle Invasive Bladder CancerManagement of Non-Muscle Invasive Bladder Cancer
Pathology of Bladder Cancers, stages of bladder cancer, non-muscle invasive bladder cancer (NMIBC), personalized therapy for NMIBC, expected side effects of TURBT, costs involved for the management of bladder cancer.
https://www.urotoday.com/library-resources/bladder-cancer/109995-management-of-non-muscle-invasive-bladder-cancer.html
MP08-04: Purified protein derivative skin test prio ... ts with non-muscle invasive bladder cancer (APL - 2018) | AUA UniversityMP08-04: Purified protein derivative skin test prio ... ts with non-muscle invasive bladder cancer (APL - 2018) | AUA University
View Poster. INTRODUCTION. Little is known about the clinical impact of the purified protein derivative (PPD) skin test prior to BCG therapy in patients with non-muscle invasive bladder cancer (NMIBC) treated with adjuvant BCG therapy.. METHODS. A total of 498 NMIBC patients initially treated with adjuvant BCG therapy at our institute between 1990 and 2015 were included. Of them, 320 (64.3%) had received the PPD skin test prior to BCG therapy (PPD group), while 178 (35.7%) patients had not (non-PPD group). The PPD skin test was performed 1 to 2 weeks prior to the start of adjuvant BCG therapy. We evaluated the association between PPD skin test performed or not performed and clinical outcomes including oncological outcomes and the incidence of BCG-related side effects in NMIBC patients treated with BCG therapy. RESULTS. Patients in the PPD group had a significantly higher incidence of pT1 (40.6%) and lower incidence of concomitant CIS (16.9%) as compared to those in the non-PPD group (28.1% and ...
https://auau.auanet.org/content/mp08-04-purified-protein-derivative-skin-test-prio-ts-non-muscle-invasive-bladder-cancer-apl
Monopolar vs. bipolar transurethral resection for non-muscle invasive bladder carcinoma: A post-hoc analysis from a randomized...Monopolar vs. bipolar transurethral resection for non-muscle invasive bladder carcinoma: A post-hoc analysis from a randomized...
Monopolar vs. bipolar transurethral resection for non-muscle invasive bladder carcinoma: A post-hoc analysis from a randomized controlled trial.
https://scholars.duke.edu/display/pub1313956
Management of recurrent or persistent non-muscle invasive bladder cancerManagement of recurrent or persistent non-muscle invasive bladder cancer
Approximately 70 percent of new urothelial (formerly called transitional cell) bladder cancer cases are classified as non-muscle invasive. Non-muscle invasive bladder cancer includes Ta, T1 (submucosal invasive) tumors, and Tis (carcinoma in situ [CI
https://www.uptodate.com/contents/management-of-recurrent-or-persistent-non-muscle-invasive-bladder-cancer
NOVEL INTRAVESICAL THERAPY FOR NON MUSCLE INVASIVE BLADDER CANCER: COMBINATION OF A FUSOGENIC GLYCOPROTEIN, PRO-DRUG ACTIVATION...NOVEL INTRAVESICAL THERAPY FOR NON MUSCLE INVASIVE BLADDER CANCER: COMBINATION OF A FUSOGENIC GLYCOPROTEIN, PRO-DRUG ACTIVATION...
Horvath, A, Simpson, GR, Coffin, RS, Mostafid, H and Pandha, H (2009) NOVEL INTRAVESICAL THERAPY FOR NON MUSCLE INVASIVE BLADDER CANCER: COMBINATION OF A FUSOGENIC GLYCOPROTEIN, PRO-DRUG ACTIVATION AND ONCOLYTIC HERPES SIMPLEX VIRUS ...
http://epubs.surrey.ac.uk/821719/
The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies | BMC Genomics | Full TextThe UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies | BMC Genomics | Full Text
Urothelial bladder cancer is a highly heterogeneous disease. Cancer cell lines are useful tools for its study. This is a comprehensive genomic characterization of 40 urothelial bladder carcinoma (UBC) cell lines including information on origin, mutation status of genes implicated in bladder cancer (FGFR3, PIK3CA, TP53, and RAS), copy number alterations assessed using high density SNP arrays, uniparental disomy (UPD) events, and gene expression. Based on gene mutation patterns and genomic changes we identify lines representative of the FGFR3-driven tumor pathway and of the TP53/RB tumor suppressor-driven pathway. High-density array copy number analysis identified significant focal gains (1q32, 5p13.1-12, 7q11, and 7q33) and losses (i.e. 6p22.1) in regions altered in tumors but not previously described as affected in bladder cell lines. We also identify new evidence for frequent regions of UPD, often coinciding with regions reported to be lost in tumors. Previously undescribed chromosome X losses found in
https://bmcgenomics.biomedcentral.com/articles/10.1186/s12864-015-1450-3/tables/3
Cohort profile: The Swedish National Register of Urinary Bladder Cancer (SNRUBC) and the Bladder Cancer Data Base Sweden ...Cohort profile: The Swedish National Register of Urinary Bladder Cancer (SNRUBC) and the Bladder Cancer Data Base Sweden ...
Purpose To monitor the quality of bladder cancer care, the Swedish National Register of Urinary Bladder Cancer (SNRUBC) was initiated in 1997. During 2015, in order to study trends in incidence, effects of treatment and survival of men and women with bladder cancer, we linked the SNRUBC to other national healthcare and demographic registers and constructed the Bladder Cancer Data Base Sweden (BladderBaSe). Participants The SNRUBC is a nationwide register with detailed information on 97% of bladder cancer cases in Sweden as compared with the Swedish Cancer Register. Participants in the SNRUBC have registered data on tumour characteristics at diagnosis, and for 98% of these treatment data have been captured. From 2009, the SNRUBC holds data on 88% of eligible participants for follow-up 5 years after diagnosis of non-muscle invasive bladder cancer, and from 2011, data on surgery details and complications for 85% of participants treated with radical cystectomy. The BladderBaSe includes all data in ...
http://liu.diva-portal.org/smash/record.jsf?pid=diva2%3A1153658&c=16&searchType=ORGANISATION&language=en&query=&af=%5B%5D&aq=%5B%5B%7B%22organisationId%22%3A%22872470%22%7D%5D%5D&aq2=%5B%5B%5D%5D&aqe=%5B%5D&noOfRows=50&sortOrder=author_sort_asc&sortOrder2=title_sort_asc&onlyFullText=false&sf=all
BCG Immunotherapy Against Non-Muscle Invasive Bladder Cancer: Recent Results, Current Studies and Future Perspectives<...
TY - JOUR. T1 - BCG Immunotherapy Against Non-Muscle Invasive Bladder Cancer. T2 - Recent Results, Current Studies and Future Perspectives. AU - Takeuchi, Ario. AU - Shiota, Masaki. AU - Tatsugami, Katsunori. AU - Yokomizo, Akira. AU - Eto, Masatoshi. PY - 2016/1/1. Y1 - 2016/1/1. UR - http://www.scopus.com/inward/record.url?scp=84979097020&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=84979097020&partnerID=8YFLogxK. M3 - Review article. C2 - 27333654. AN - SCOPUS:84979097020. VL - 107. SP - 8. EP - 11. JO - Fukuoka Acta Medica. JF - Fukuoka Acta Medica. SN - 0016-254X. IS - 1. ER - ...
https://kyushu-u.pure.elsevier.com/ja/publications/bcg-immunotherapy-against-non-muscle-invasive-bladder-cancer-rece
Different parents, different children: Muscle-invasive and non-muscle invasive bladder cancers arise from different stem cells ...Different parents, different children: Muscle-invasive and non-muscle invasive bladder cancers arise from different stem cells ...
Bladder cancer will kill upward of 170,000 people worldwide this year, but bladder cancer isnt fatal in the bladder. Instead, in order to be fatal the disease must metastasize to faraway sites. The question has been this: does localized, non-muscle invasive (NMI) bladder cancer eventually become the more dangerous, muscle-invasive (MI) form of the disease, or are NMI and MI bladder cancers genetically distinct from the start?. A University of Colorado Cancer Center study published today in the journal Stem Cells shows its the latter: the progenitor cells that create MI bladder cancer are different than the progenitor cells that create NMI bladder cancer. Though these two cancers grow at the same site, they are different diseases.. This work provides an important new perspective on how we look at bladder cancer biology, says Dan Theodorescu, MD, PhD, director of the University of Colorado Cancer Center and the studys senior author.. The group including first author Garrett Dancik, PhD, ...
http://www.coloradocancerblogs.org/different-parents-different-children-muscle-invasive-non-muscle-invasive-bladder-cancers-arise-different-stem-cells/
Influences of Different Operative Methods on the Recurrence Rate of Non-Muscle-Invasive Bladder Cancer | Urology Journal...Influences of Different Operative Methods on the Recurrence Rate of Non-Muscle-Invasive Bladder Cancer | Urology Journal...
Maurice MJ, Vricella GJ, MacLennan G, Buehner P, Ponsky LE. Endoscopic snare resection of bladder tumors: evaluation of an alternative technique for bladder tumor resection. Journal of endourology. 2012;26:614-7. Bai Y, Liu L, Yuan H, et al. Safety and efficacy of transurethral laser therapy for bladder cancer: a systematic review and meta-analysis. World journal of surgical oncology. 2014;12:301. Lopez-Beltran A, Montironi R. Non-invasive urothelial neoplasms: according to the most recent WHO classification. European urology. 2004;46:170-6. DUTTA SC, SMITH JA, SHAPPELL SB, COFFEY CS, CHANG SS, COOKSON MS. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. The Journal of urology. 2001;166:490-3. Suer E, Hamidi N, Gokce MI, et al. Significance of second transurethral resection on patient outcomes in muscle-invasive bladder cancer patients treated with bladder-preserving multimodal therapy. World journal of urology. 2016;34:847-51. Chen J, ...
https://journals.sbmu.ac.ir/urolj/index.php/uj/article/view/5965
Determination of Apoptotic Effect of Juglone on Human Bladder Cancer TCC-SUP and RT-4 Cells: An In Vitro Study | AVESİSDetermination of Apoptotic Effect of Juglone on Human Bladder Cancer TCC-SUP and RT-4 Cells: An In Vitro Study | AVESİS
This study aimed to investigate the effects of juglone on the human bladder carcinoma cell lines TCC-SUB and RT-4 in monolayer and spheroid cultures. Cells were treated with juglone at 24,48, and 72 h of incubation. The activity of caspase-3 was detected in vitro using a caspase-3 colorimetric assay kit according to the manufacturers instructions. The bromodeoxyuridine (BrdU) labeling index was used to determine the cells of the synthesis phase. The terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling assay was used to determine the death of cells in both the monolayer and spheroid cultures. The control group had a large S-phase fraction and many of the TCC-SUB and RT-4 cells nuclei were observed to be positive for BrdU. The dead cell count was higher in the TCC-SUB and RT-4 cell lines with juglone applied than in the controls. We conclude that juglone significantly inhibits the proliferation and induces the apoptosis of TCC-SUB and RT-4 cells in vitro. ...
https://avesis.sdu.edu.tr/yayin/b0239555-c423-4f5b-bdd7-f13fde4b7f41/determination-of-apoptotic-effect-of-juglone-on-human-bladder-cancer-tcc-sup-and-rt-4-cells-an-in-vitro-study
A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer - Full Text View ...A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer - Full Text View ...
This is a Phase Ib/II, open-label, multi-center and competitive enrollment study of ALT-801 combined with gemcitabine for patients who have BCG failure (defined as refractory, relapsing or intolerant), non-muscle invasive bladder cancer and refuse or are not medically fit to undergo a radical cystectomy recommended by the participating urologist as the standard next therapy per urologic guidelines. The purpose of this study is to confirm the safety and tolerability of a well-tolerated dose level of ALT-801, to determine the Recommended Dose level (RD) and characterize the immunogenicity of ALT-801 combined with gemcitabine in treated patients. The anti-tumor responses will also be assessed ...
https://clinicaltrials.gov/ct2/show/study/NCT01625260
Autophagy and urothelial carcinoma of the bladder: A review<...
TY - JOUR. T1 - Autophagy and urothelial carcinoma of the bladder. T2 - A review. AU - Chandrasekar, Thenappan. AU - Evans, Christopher P. PY - 2016. Y1 - 2016. N2 - The incidence of urothelial carcinoma of the urinary bladder (bladder cancer) remains high. While other solid organ malignancies have seen significant improvement in morbidity and mortality, there has been little change in bladder cancer mortality in the past few decades. The mortality is mainly driven by muscle invasive bladder cancer, but the cancer burden remains high even in nonmuscle invasive bladder cancer due to high recurrence rates and risk of progression. While apoptosis deregulation has long been an established pathway for cancer progression, nonapoptotic pathways have gained prominence of late. Recent research in the role of autophagy in other malignancies, including its role in treatment resistance, has led to greater interest in the role of autophagy in bladder cancer. Herein, we summarize the literature regarding the ...
https://ucdavis.pure.elsevier.com/en/publications/autophagy-and-urothelial-carcinoma-of-the-bladder-a-review
Identification of S100A8 -correlated genes for prediction of disease progression in non-muscle invasive bladder cancer | BMC...Identification of S100A8 -correlated genes for prediction of disease progression in non-muscle invasive bladder cancer | BMC...
S100 calcium binding protein A8 (S100A8) has been implicated as a prognostic indicator in several types of cancer. However, previous studies are limited in their ability to predict the clinical behavior of the cancer. Here, we sought to identify a molecular signature based on S100A8 expression and to assess its usefulness as a prognostic indicator of disease progression in non-muscle invasive bladder cancer (NMIBC). We used 103 primary NMIBC specimens for microarray gene expression profiling. The median follow-up period for all patients was 57.6 months (range: 3.2 to 137.0 months). Various statistical methods, including the leave-one-out cross validation method, were applied to identify a gene expression signature able to predict the likelihood of progression. The prognostic value of the gene expression signature was validated in an independent cohort (n = 302). Kaplan-Meier estimates revealed significant differences in disease progression associated with the expression signature of S100A8-correlated
https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-10-21/figures/3
Muscle Invasive Bladder CancerMuscle Invasive Bladder Cancer
Muscle invasive bladder cancer (MIBC) is a cancer that spreads into the detrusor muscle of the bladder. The detrusor muscle is the thick muscle deep in the bladder wall. This cancer is more likely to spread to other parts of the body. About 1 out of 4 people who get bladder cancer in the United States have the muscle invasive kind.
https://www.urologyhealth.org/urologic-conditions/muscle-invasive-bladder-cancer
DAB2IP regulates the chemoresistance to pirarubicin and tumor recurrence of non-muscle invasive bladder cancer through STAT3...
Fingerprint Dive into the research topics of DAB2IP regulates the chemoresistance to pirarubicin and tumor recurrence of non-muscle invasive bladder cancer through STAT3/Twist1/P-glycoprotein signaling. Together they form a unique fingerprint. ...
https://utsouthwestern.pure.elsevier.com/en/publications/dab2ip-regulates-the-chemoresistance-to-pirarubicin-and-tumor-rec/fingerprints/
FDA Approves Keytruda for High-Risk, Non-Muscle Invasive Bladder CancerFDA Approves Keytruda for High-Risk, Non-Muscle Invasive Bladder Cancer
The Food and Drug Administration approved Keytruda for the treatment of patients with Bacillus Calmette-Guerin–unresponsive, high-risk, non-muscle invasive bladder cancer.|br /|  
https://www.curetoday.com/articles/fda-approves-keytruda-for-highrisk-nonmuscle-invasive-bladder-cancer
Silencing of ECHDC1 inhibits growth of gemcitabine‑resistant bladder cancer cellsSilencing of ECHDC1 inhibits growth of gemcitabine‑resistant bladder cancer cells
The human bladder cancer cell lines, UMUC3 and HT1376, which were used in this study, were purchased from DS Pharma Biomedical (Osaka, Japan). UMUC3 cells were maintained in minimum essential medium (MEM) supplemented with MEM non-essential amino acids (NEAA) and sodium pyruvate (Gibco, St. Louis, MO, USA). HT1376 cells were maintained in RPMI-1640 medium (Wako, Osaka, Japan). Both media were supplemented with 10% FBS (Sigma-Aldrich, St. Louis, MO, USA). The cells were incubated in a humidified incubator at 37°C in an atmosphere of 5% CO2 and 95% air. Each gemcitabine-resistant cell line (GR) was obtained from the parental UMUC3 or HT1376 cells.. The UMUC3 and HT1376 cells were grown in cell culture media containing gemcitabine (Wako), starting with a concentration of 10-2 µM. The cells were then passaged through stepwise increasing concentrations of gemcitabine up to a concentration of 50 µM. The cells were repeatedly passaged at each gemcitabine concentration in the stepwise ...
https://www.spandidos-publications.com/ol/15/1/522
Disease Graphics, Videos & Images on Bladder NeoplasmDisease Graphics, Videos & Images on Bladder Neoplasm
DiseaseFix brings interesting disease graphics, videos, pictures, photos, and images on Bladder Neoplasm. Watch graphics along with explanatory content at one place for Bladder Neoplasm. Causes, Symptoms, Diagnosis, Treatment.
http://www.diseasefix.com/graphics/bladder-neoplasm/76/1/
Institute of Cancer Research Repository - Modification of Occupational Exposures on Bladder Cancer Risk by Common Genetic...
Few studies have demonstrated gene/environment interactions in cancer research. Using data on high-risk occupations for 2258 case patients and 2410 control patients from two bladder cancer studies, we observed that three of 16 known or candidate bladder cancer susceptibility variants displayed statistically significant and consistent evidence of additive interactions; specifically, the GSTM1 deletion polymorphism (P-interaction ,= .001), rs11892031 (UGT1A, P-interaction = .01), and rs798766 (TMEM129-TACC3-FGFR3, P-interaction = .03). There was limited evidence for multiplicative interactions. When we examined detailed data on a prevalent occupational exposure associated with increased bladder cancer risk, straight metalworking fluids, we also observed statistically significant additive interaction for rs798766 (TMEM129-TACC3-FGFR3, P-interaction = .02), with the interaction more apparent in patients with tumors positive for FGFR3 expression. All statistical tests were two-sided. The interaction ...
http://publications.icr.ac.uk/14710/
Muscle Invasive Bladder Cancer - Bladder Cancer Support ForumMuscle Invasive Bladder Cancer - Bladder Cancer Support Forum
Hi I am new to this forum and wondered if I could get some support from this forum. My mother has recently been diagnosed with muscle invasive bladder cancer in...
https://bladdercancersupport.org/forum/3-newly-diagnosed/46707-muscle-invasive-bladder-cancer.html
Study of cancer cell lines with Fourier transform infrared (FTIR)/vibrational absorption (VA) spectroscopy - DTU OrbitStudy of cancer cell lines with Fourier transform infrared (FTIR)/vibrational absorption (VA) spectroscopy - DTU Orbit
In this work we have used Fourier transform infrared (FTIR) / vibrational absorption (VA) spectroscopy to study two cancer cell lines: the Henrietta Lacks (HeLa) human cervix carcinoma and 5637 human bladder carcinoma cell lines. Our goal is to experimentally investigate biochemical changes and differences in these cells lines utilizing FTIR spectroscopy. We have used the chemometrical and statistical method principal component analysis (PCA) to investigate the spectral differences. We have been able to identify certain bands in the spectra which are so-called biomarkers for two types of cell lines, three groups for the 5637 human bladder carcinoma cell line (5637A, 5637B and 5637C), and another one for the HeLa human cervix carcinoma cell line. The vibrational modes can be assigned to specific bands involving characteristic motions of the protein backbone. This work shows that infrared vibrational absorption (VA) spectroscopy can be used as a useful tool in medical diagnostics that provides in ...
http://orbit.dtu.dk/en/publications/study-of-cancer-cell-lines-with-fourier-transform-infrared-ftirvibrational-absorption-va-spectroscopy
Superimposed histologic and genetic mapping of chromosome 17 alterations in human urinary bladder neoplasia<...Superimposed histologic and genetic mapping of chromosome 17 alterations in human urinary bladder neoplasia<...
TY - JOUR. T1 - Superimposed histologic and genetic mapping of chromosome 17 alterations in human urinary bladder neoplasia. AU - Chaturvedi, Vijaya. AU - Li, Li. AU - Hodges, Sherie. AU - Johnston, Dennis. AU - Ro, Jae Y.. AU - Logothetis, Christopher. AU - Von Eschenbach, Andrew C.. AU - Batsakis, John G.. AU - Czerniak, Bogdan. PY - 1997. Y1 - 1997. N2 - Multistep alterations of chromosome 17 in the progression of human urinary bladder neoplasia were studied by superimposed histologic and genetic mapping. The p53 gene was included in the analysis as a model tumor suppressor gene that is frequently involved in urothelial carcinogenesis. The strategy provided a systematic approach to the study of multistep genomic alterations that occur as neoplasia progresses from precursor intraurothelial conditions to invasive cancer. This was accomplished by sampling the entire mucosa of the organ and displaying microscopically identified invasive cancer and precursor conditions in the form of a histologic ...
https://scholars.houstonmethodist.org/en/publications/superimposed-histologic-and-genetic-mapping-of-chromosome-17-alte
Non Muscle Invasive Bladder Cancer (NMIBC) - knowledge base - URO ONCONon Muscle Invasive Bladder Cancer (NMIBC) - knowledge base - URO ONCO
Publications, guidelines and educational videos on Non Muscle Invasive Bladder Cancer (NMIBC). Open access. Content provided by Elsevier.
http://uroonco.com/nmibc
G9a Inhibition Has Antitumor Activity in Bladder Cancer | Cancer DiscoveryG9a Inhibition Has Antitumor Activity in Bladder Cancer | Cancer Discovery
There are limited established therapies for bladder cancer, which can be lethal if it reaches advanced stages and invades surrounding muscle tissue. Segovia, San José-Enériz, Munera-Maravilla, and colleagues found that expression of the histone methyltransferase G9a, suggested in prior studies to be a bladder cancer oncoprotein, was higher in human non-muscle-invasive bladder cancer tumors than in adjacent healthy tissue, and higher levels of the G9a mRNA and protein were correlated with increased chance of bladder cancer recurrence. CM-272, a G9a/DNMT inhibitor, inhibited cell proliferation in some bladder cancer cell lines, and cell lines resistant to CM-272 had mutations in PIK3CA. Because G9a and EZH2 coregulate H3K27me3 and activating mutations in PIK3CA reduce EZH2 and H3K27me3 in bladder cancer, CM-272 resistance may be related to EZH2 activity; supporting this, PIK3CA-mutant bladder cancer cells had decreased EZH2 levels, and PIK3CA-mutant bladder cancer cells exhibited EZH2 ...
https://cancerdiscovery.aacrjournals.org/content/early/2019/07/12/2159-8290.CD-RW2019-105.full
Gambogic acid-induced apoptosis and cell arrest in human bladder cancer cell - Minerva Biotecnologica 2015 September;27(3):137...
METHODS: Human bladder cancer BIU-87 cell lines were cultured in vitro. Different concentrations of gambogic acids were added to the logarithmic growth phase in the human bladder cancer BIU-87 cells for further cultivation. Caspase-3 protein expression in tumor tissue was detected by immunohistochemical S-P method. The gambogic acid-induced apoptosis in human bladder cancer cells and cell cycle changes were detected and analyzed using flow cytometry ...
https://www.minervamedica.it/it/riviste/minerva-biotecnologica/articolo.php?cod=R04Y2015N03A0137
Photocure with exciting news: FDA-approval of new packaging for bladder cancer product - Oslo Cancer Cluster - IncubatorPhotocure with exciting news: FDA-approval of new packaging for bladder cancer product - Oslo Cancer Cluster - Incubator
Bladder cancer is the fifth most common cancer in men with more than 330 000 new cases annually and more than 130 000 die of the disease1. It has a high recurrence rate with an average of 61% in one year and 78% over five years, making the lifetime costs of managing bladder cancer one of the highest amongst all cancers. It is a costly, potentially progressive disease for which patients have to undergo multiple cystoscopies because of the high risk of recurrence.. A recent paper on the economic burden of bladder cancer across the European Union estimates that bladder cancer cost the EU 4.9 billion Euro in 2012. There is an urgent need to improve both the diagnosis and the management of bladder cancer for the benefit of patients and healthcare systems alike.. Bladder cancer is classified into two types, non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of invasion in the bladder wall. NMIBC is still in the inner layer of cells. These ...
https://occincubator.com/photocure-with-exciting-news-fda-approval-of-new-packaging-for-bladder-cancer-product/
Bladder Cancer - A Womans Health - Women MagazineBladder Cancer - A Womans Health - Women Magazine
The wall of the bladder is lined with several layers of cells called transitional cells. Cancer arising from these cells makes up more than 90% of all bladder cancers and these are referred to as transitional cell carcinomas. Because transitional cell carcinomas are the most common type of bladder cancer, the information in this section only addresses treatment of transitional cell cancer of the bladder. Bladder cancer occurs predominantly in elderly men and less frequently in women and younger men. Many bladder cancers are thought to be caused by exposure to cancer-causing agents that pass through the urine and come into contact with the bladder lining. The most important risk factor for bladder cancer is smoking, which increases risk by at least four-fold.[1]. The most common sign of bladder cancer is hematuria or blood in the urine, which will turn the urine rust or red in color.[2] Other signs of bladder cancer may include pain during urination and frequent urination. Most patients with ...
http://awomanshealth.com/conditions-treatments/bladder-cancer/
Non Muscle Invasive Bladder Cancer Emerging Drugs, 2020 - Northern India HeraldNon Muscle Invasive Bladder Cancer Emerging Drugs, 2020 - Northern India Herald
Non-Muscle Invasive Bladder Cancer (NMIBC) is a common, heterogeneous disease associated with high rates of recurrence that often requires lifelong surveillance. The cancer is found in the tissue that lines the inner surface of the bladder wherein the bladder muscle is not involved.. The high-grade NMIBC pipeline possesses potential drugs in mid and late stage developments to be launched in the near future. The major key players include Viventia Bio/Sesen Bio (Vicinium), FKD Therapies Oy/Ferring Pharmaceuticals (Adstiladrin), CG Oncology (CG0070), ImmunityBio/Altor Biosciences (N-803 (ALT-803)), Theralase (TLD-1433), Merck (Keytruda) and others that hold the potential to create a significant positive shift in NMIBC in the market size.. Keytruda is developed by Merck and marketed in the United States which is a humanized monoclonal antibody that binds to the programmed cell death- 1 (PD-1) receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the ...
http://www.northernindiaherald.in/story/99217/non-muscle-invasive-bladder-cancer-emerging-drugs-2020.html
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label,...
TY - JOUR. T1 - Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010). T2 - a multicentre, open-label, randomised, phase 3 trial. AU - IMvigor010 Study Group. AU - Bellmunt, Joaquim. AU - Hussain, Maha. AU - Gschwend, Jürgen E.. AU - Albers, Peter. AU - Oudard, Stephane. AU - Castellano, Daniel. AU - Daneshmand, Siamak. AU - Nishiyama, Hiroyuki. AU - Majchrowicz, Martin. AU - Degaonkar, Viraj. AU - Shi, Yi. AU - Mariathasan, Sanjeev. AU - Grivas, Petros. AU - Drakaki, Alexandra. AU - ODonnell, Peter H.. AU - Rosenberg, Jonathan E.. AU - Geynisman, Daniel M.. AU - Petrylak, Daniel P.. AU - Hoffman-Censits, Jean. AU - Bedke, Jens. AU - Kalebasty, Arash Rezazadeh. AU - Zakharia, Yousef. AU - van der Heijden, Michiel S.. AU - Sternberg, Cora N.. AU - Davarpanah, Nicole N.. AU - Powles, Thomas. N1 - Funding Information: This study was supported by F Hoffmann-La Roche/Genentech, a member of the Roche Group. We thank the patients who participated in the trial ...
https://www.scholars.northwestern.edu/en/publications/adjuvant-atezolizumab-versus-observation-in-muscle-invasive-uroth
Hypermethylation of Multiple Genes in Tumor Tissues and Voided Urine in Urinary Bladder Cancer Patients | Clinical Cancer...Hypermethylation of Multiple Genes in Tumor Tissues and Voided Urine in Urinary Bladder Cancer Patients | Clinical Cancer...
We have analyzed the methylation pattern of RARβ, DAPK, E-cadherin, p15, p16, MGMT, and GSTP1 in bladder TCC of different stages and grades. In our study, all of our samples have at least one gene methylated, and more than three genes that were methylated accounted for 20% of our cases. Thus, the epigenetic event of gene methylation was frequent in bladder cancer. However, this phenomenon did not appear to be correlated with disease grade or stage.. Reports on the methylation of various genes have been described in primary bladder cancer (12, 13, 14, 15, 16, 17, 18, 19) . Among these reports, methylation of p16 was most commonly investigated. The frequency of p16 methylation in bladder TCC ranged from 9-67% (13, 14, 15, 16, 17 , 19) . Our study represented the largest series and demonstrated p16 methylation of 26.5%. Tumor suppressor gene p16 specifically inactivates cyclin-dependent kinase 4 and cyclin-dependent kinase 6, which interact with cyclin D1 and stimulate the progression of the cell ...
https://clincancerres.aacrjournals.org/content/8/2/464?ijkey=e07f632dd47ec4b4cad4f2d1267db785d8696498&keytype2=tf_ipsecsha
Overexpression of Pim-1 in bladder cancer | Journal of Experimental & Clinical Cancer Research | Full TextOverexpression of Pim-1 in bladder cancer | Journal of Experimental & Clinical Cancer Research | Full Text
In the present study we demonstrated for the first time that, Pim-1 was increased in human bladder cancer epithelium as compared with that in normal bladder tissue. When the tumors were stratified by Non-invasive and invasive, a statistically significant increase of Pim-1 expression was found in the subgroup of invasive tumor when compared with that in the Non-invasive tumor. Pim-1 was also detected in all human bladder cancer cell lines tested in our study. Knockdown Pim-1 led to decreased phosphorylation of Bad and reduced expression of Bcl-2. Furthermore, downregulation of Pim-1 inhibited the bladder cancer cells growth and sensitized them to chemotherapy in vitro. Further evaluation of the prognostic significance of Pim-1 in a larger cohort with sufficient follow-up times will allow better understand of the clinical significance of Pim-1.. Overexpression of the Pim-1 protein has been reported in hematolymphoid malignancies and solid cancers [4, 5]. Pim-1 has been asserted to promote ...
https://jeccr.biomedcentral.com/articles/10.1186/1756-9966-29-161
Adjuvant Chemotherapy After Radical Cystectomy for Urothelial Bladder Cancer: Outcome and Prognostic Factors for Survival in a...Adjuvant Chemotherapy After Radical Cystectomy for Urothelial Bladder Cancer: Outcome and Prognostic Factors for Survival in a...
p,,b,BACKGROUND: ,/b,In the past decade, adjuvant chemotherapy (AC) after radical cystectomy (RC) was preferred worldwide for patients with muscle-invasive urothelial bladder cancer. In this study we aimed to determine the outcome of patients who received AC and evaluated prognostic factors associated with survival.,/p,,p,,b,PATIENTS AND METHODS: ,/b,We retrospectively analyzed 226 consecutive patients treated in 6 academic hospitals between 2000 and 2009. Multivariate Cox proportional hazards regression adjusted for center to estimate adjusted hazard ratios (HRs) with 95% confidence intervals were used.,/p,,p,,b,RESULTS: ,/b,The median age was 62.4 (range, 35-82) years. Patients had pT3/pT4 and/or pN+ in 180 (79.6%) and 168 patients (74.3%), respectively. Median lymph node (LN) density was 25% (range, 3.1-100). Median time between RC and AC was 61.5 (range, 18-162) days. Gemcitabine with cisplatin, gemcitabine with carboplatin, and MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin) ...
http://www.cepia.team/content/adjuvant-chemotherapy-after-radical-cystectomy-urothelial-bladder-cancer-outcome-and
Treatment of Non Muscle Invasive Bladder Tumor Related to the Problem of Bacillus Calmette-Guerin Availability. Consensus of a...Treatment of Non Muscle Invasive Bladder Tumor Related to the Problem of Bacillus Calmette-Guerin Availability. Consensus of a...
Treatment of Non Muscle Invasive Bladder Tumor Related to the Problem of Bacillus Calmette-Guerin Availability. Consensus of a Spanish Experts ...
https://digibuo.uniovi.es/dspace/handle/10651/19672?show=full
Analysis of differential PDT effect in rat bladder tumor models according to concentrations of intravesical hexyl...Analysis of differential PDT effect in rat bladder tumor models according to concentrations of intravesical hexyl...
The hexylester of 5-aminolevulinic acid (HAL) is a very efficient precursor of the photosensitizer protoporphyrin IX (PpIX) for photodynamic therapy (PDT). Our previous study, performed in rat orthotopic bladder tumors, indicated an opposite effect of HAL/PpIX-PDT according to HAL concentration. The present study investigated possible reasons for this differential effect considering the impact of extracted amounts of PpIX in normal and tumor bearing bladders along with PpIX distribution in distinctive histopathological layers. High performance liquid chromatography (HPLC) analysis of tumor and normal bladder tissues after 8 mM and 16 mM HAL instillation showed that PpIX was the main porphyrin species. The PpIX production in tumor bladders instilled with 8 mM HAL was significantly higher than after 16 mM HAL. Fluorescence confocal microscopy demonstrated a punctuate bright fluorescence pattern in tumor zones of bladders instilled with 8 mM HAL, whereas a more diffuse cytoplasmatic fluorescence
https://www.semanticscholar.org/paper/Analysis-of-differential-PDT-effect-in-rat-bladder-Berrahmoune-Fotinos/aace60d640ff62c41482e5880cde5bfaa149972e
P16P16
However, p16 can be expressed in other neoplasms and in several normal human tissues. More than a third of urinary bladder SCCs ... SCCs of urinary bladder express p16 independent of gender. p16 immunohistochemical expression alone cannot be used to ... "Hypermethylation of p16 and DAPK promoter gene regions in patients with non-invasive urinary bladder cancer". Archives of ... discriminate between SCCs arising from uterine cervix versus urinary bladder. Concentrations of p16INK4a increase dramatically ...
https://en.wikipedia.org/wiki/P16
Polyp (medicine)Polyp (medicine)
Polyps are commonly found in the colon, stomach, nose, ear, sinus(es), urinary bladder, and uterus. They may also occur ... Some polyps are tumors (neoplasms) and others are non-neoplastic, for example hyperplastic or dysplastic, which are benign. The ...
https://en.wikipedia.org/wiki/Polyp_(medicine)
Bladder cancerBladder cancer
... neoplasms of the urinary bladder. Bladder Consensus Conference Committee". The American Journal of Surgical Pathology. 22 (12 ... Bladder cancer is any of several types of cancer arising from the tissues of the urinary bladder. Symptoms include blood in the ... "Cancer of the Urinary Bladder - Cancer Stat Facts". SEER. Retrieved 30 October 2019. "Bladder Cancer Factsheet" (PDF). Global ... "Bladder Preservation for Muscle Invasive Bladder Cancer". Bladder Cancer. 2 (2): 151-163. doi:10.3233/BLC-150025. PMC 4927909. ...
https://en.wikipedia.org/wiki/Bladder_cancer
Transitional cell carcinomaTransitional cell carcinoma
Histopathology of urothelial carcinoma of the urinary bladder. Histopathology of urothelial carcinoma of the urinary bladder. ... papillary neoplasm of low malignant potential [PNLMP], low grade, and high grade papillary carcinoma). Papillary transitional ... Punyavoravut V, Nelson SD (August 1999). "Diffuse bony metastasis from transitional cell carcinoma of urinary bladder: a case ... It is the most common type of bladder cancer and cancer of the ureter, urethra, and urachus. It accounts for 95% of bladder ...
https://en.wikipedia.org/wiki/Transitional_cell_carcinoma
Papillary urothelial neoplasm of low malignant potentialPapillary urothelial neoplasm of low malignant potential
... urinary bladder and part of the urethra. PUNLMP is pronounced pun-lump, like the words pun and lump. As their name suggests, ... Papillary urothelial neoplasm of low malignant potential (PUNLMP) is an exophytic (outward growing), (microscopically) nipple- ... MacLennan GT, Kirkali Z, Cheng L (April 2007). "Histologic grading of noninvasive papillary urothelial neoplasms". Eur. Urol. ... PUNLMPs are neoplasms, i.e. clonal cellular proliferations, that are thought to have a low probability of developing into ...
https://en.wikipedia.org/wiki/Papillary_urothelial_neoplasm_of_low_malignant_potential
Krukenberg tumorKrukenberg tumor
... and urinary bladder or gallbladder, biliary tract, pancreas, ampulla of Vater or uterine cervix. Immunohistochemistry may help ... in diagnosing Krukenberg tumors from primary ovarian neoplasms but needs to be applied with discretion. For example, tumors ...
https://en.wikipedia.org/wiki/Krukenberg_tumor
CSNK1DCSNK1D
Also decreased CK1δ mRNA expression levels have been observed in some cancer studies, like urinary bladder cancer, lung ... hematopoietic malignancies and lymphoid neoplasms. ... among them bladder cancer, brain cancer, breast cancer, ...
https://en.wikipedia.org/wiki/CSNK1D
Urogenital neoplasmUrogenital neoplasm
Cancer of the urinary organs (Bladder cancer, Renal cell carcinoma) Kurman RJ (2013). Blaustein's Pathology of the Female ... A urogenital neoplasm is a tumor of the urogenital system. Types include: Cancer of the female genital organs: (Cervical cancer ... Neoplasm stubs, Disease stubs, Genitourinary system stubs). ...
https://en.wikipedia.org/wiki/Urogenital_neoplasm
Nuclear grooveNuclear groove
... papillary transitional cell carcinoma of the urinary bladder, papillary renal cell carcinoma, papillary endometrioid carcinoma ... Breast carcinomas Vaginal, cervical and/or endometrial neoplasms Papillary neoplasms of several organs: ... It can be present in: Thyroid neoplasms: It is a characteristic feature of papillary thyroid carcinoma, but has also been seen ... in other types of thyroid neoplasms, as well as in non-neoplastic thyroid lesions. Ovarian tumors including Brenner tumors, ...
https://en.wikipedia.org/wiki/Nuclear_groove
Somatic evolution in cancerSomatic evolution in cancer
Habuchi T (August 2005). "Origin of multifocal carcinomas of the bladder and upper urinary tract: molecular analysis and ... which may be benign neoplasms) or else a malignant neoplasm (cancer). These neoplasms are also indicated, in the diagram below ... In bladder cancer, clones with loss of p16 were observed to have spread over the entire surface of the bladder. Likewise, large ... February 1999). "Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia ...
https://en.wikipedia.org/wiki/Somatic_evolution_in_cancer
Route of administrationRoute of administration
Intravesical infusion is into the urinary bladder. Intravitreal, through the eye. Subcutaneous (under the skin). This generally ... Intraocular, into the eye, e.g., some medications for glaucoma or eye neoplasms. Intraosseous infusion (into the bone marrow) ...
https://en.wikipedia.org/wiki/Route_of_administration
Harrisons Principles of Internal MedicineHarrison's Principles of Internal Medicine
Bladder Pain, and the Interstitial Cystitis/Bladder Pain Syndrome Chapter 48: Azotemia and Urinary Abnormalities Chapter 49: ... Neoplasms of the Lung Chapter 75: Breast Cancer Chapter 76: Upper Gastrointestinal Tract Cancers Chapter 77: Lower ... Cancer of the Bladder and Urinary Tract Chapter 83: Benign and Malignant Diseases of the Prostate Chapter 84: Testicular Cancer ... Atlas of Urinary Sediments and Renal Biopsies Chapter A4: Atlas of Skin Manifestations of Internal Disease Chapter A5: Atlas of ...
https://en.wikipedia.org/wiki/Harrison's_Principles_of_Internal_Medicine
EndoscopeEndoscope
The urinary tract: cystitis, bladder conjugation, bladder tumor, renal tuberculosis, renal stones, renal tumors, congenital ... Small intestine: small intestine neoplasms, smooth muscle tumors, sarcomas, polyps, lymphomas, inflammation, etc. Large ... Examples include the cystoscope (bladder), nephroscope (kidney), bronchoscope (bronchus), arthroscope (joints) and colonoscope ...
https://en.wikipedia.org/wiki/Endoscope
Pelvic lipomatosisPelvic lipomatosis
Associated with cystitis glandularis, a precursor to adenocarcinoma of the urinary bladder. It is associated with deposition of ... Pelvic lipomatosis: a condition simulating pelvic neoplasm. Radiology. 1968;90:558. http://www.medscape.com/viewarticle/417016_ ... mature unencapsulated fat in the retroperitoneal pelvic space producing the typical "pear-shaped" appearance of the bladder on ...
https://en.wikipedia.org/wiki/Pelvic_lipomatosis
Small supernumerary marker chromosomeSmall supernumerary marker chromosome
... is the single most common recurrent structural chromosomal abnormality in transitional cell carcinomas of the urinary bladder, ... However, it may also be active in causing birth defects and neoplasms (e.g. tumors and cancers). The sSMC's small size makes it ... Transitional cell bladder carcinomas associated with this sSMS are more aggressive and invasive than those not associated with ... Surgical removal of the gonads has been recommended to remove the threat of developing these sSMC-associated neoplasms. Tuner ...
https://en.wikipedia.org/wiki/Small_supernumerary_marker_chromosome
List of ICD-9 codes 140-239: neoplasmsList of ICD-9 codes 140-239: neoplasms
... other male genital organs 188 Malignant neoplasm of bladder 189 Malignant neoplasm of kidney and other and unspecified urinary ... 140 Malignant neoplasm of lip 141 Malignant neoplasm of tongue 142 Malignant neoplasm of major salivary glands 143 Malignant ... of male genital organs 223 Benign neoplasm of kidney and other urinary organs 224 Benign neoplasm of eye 225 Benign neoplasm of ... benign neoplasm of uterus 220 Benign neoplasm of ovary 221 Benign neoplasm of other female genital organs 222 Benign neoplasm ...
https://en.wikipedia.org/wiki/List_of_ICD-9_codes_140–239:_neoplasms
Abdominal painAbdominal pain
... bladder infection Obstruction: kidney stones, urolithiasis, urinary retention, tumours Vascular: left renal vein entrapment ... benign or malignant neoplasms Large bowel obstruction caused by colorectal cancer, inflammatory bowel disease, volvulus, fecal ... complicated urinary tract infection Left low back pain Spleen Kidney: kidney stone (nephrolithiasis), complicated urinary tract ... bladder stone, bladder cancer, pelvic inflammatory disease, pelvic pain syndrome Gynecologic: endometriosis, intrauterine ...
https://en.wikipedia.org/wiki/Abdominal_pain
Nuclear protein in testis geneNuclear protein in testis gene
... urinary bladder, retroperitoneum (i.e. space behind the peritoneum of the abdominal cavity), endometrium, kidneys, ovaries, and ... of the neoplasms associated with the BRD4-NUTM1 fusion gene. These questions also apply to a wide range of neoplasms that have ... It is generally accepted that the BRD4-NUT protein promotes these neoplasms by maintaining their neoplastic cells in a ... Luo W, Stevens TM, Stafford P, Miettinen M, Gatalica Z, Vranic S (November 2021). "NUTM1-Rearranged Neoplasms-A Heterogeneous ...
https://en.wikipedia.org/wiki/Nuclear_protein_in_testis_gene
Abnormal urine colorAbnormal urine color
... urinary tract infection, medication, porphyria, intra-abdominal bleeding, vaginal bleeding, neoplasm located in either bladder ... For instance, cloudy or milky urine usually accompanied by bad smell possibly indicates urinary tract infection, excessive ... and urinary tract infections. Doctor may prescribe some tests to help get the full picture of the situation, such as blood ... tests, liver function tests, ultrasound for kidneys and bladder, urinalysis, urine culture for infection, and cystoscopy. ...
https://en.wikipedia.org/wiki/Abnormal_urine_color
Ureteral cancerUreteral cancer
... is cancer of the ureters, muscular tubes that propel urine from the kidneys to the urinary bladder. It is also ... Ureteral neoplasm, a type of tumor that can be primary, or associated with a metastasis from another site Urethral cancer, ... the bladder, and parts of the urethra Bladder cancer, cancer of the bladder Ureter Cancer, Mayo Clinic Ries LG, Young JL, Keel ... After surgery to remove the tumor, a single dose of chemotherapy injected into the bladder is helpful in reducing the rate of ...
https://en.wikipedia.org/wiki/Ureteral_cancer
PemigatinibPemigatinib
... protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder". Pharmacol. Res. 151: ... In the United States it is also indicated for the treatment of relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with ... "FDA approves pemigatinib for relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement". U.S. Food and Drug ... for pemigatinib for the treatment of myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1 ...
https://en.wikipedia.org/wiki/Pemigatinib
MirabegronMirabegron
... , sold under the brand name Myrbetriq among others, is a medication used to treat overactive bladder. Its benefits ... Other significant side effects include urinary retention, irregular heart rate, and angioedema. It works by activating the β3 ... Sinusitis Diarrhea High heart rate Fatigue Abdominal pain Neoplasms (cancers) Rare (. ... Mirabegron is used is in the treatment of overactive bladder. It works equally well to antimuscarinic medication such as ...
https://en.wikipedia.org/wiki/Mirabegron
Cauda equina syndromeCauda equina syndrome
Bladder and bowel dysfunction,: 216 caused by decreased tone of the urinary and anal sphincters. Detrusor weaknesses causing ... Chemotherapy can also be used for spinal neoplasms. If the syndrome is due to an inflammatory condition e.g., ankylosing ... Urinary catheterization may help with bladder control. Gravity and exercise can help control bowel movement (Hodges, 2004). ... Changes in bladder function may be changes to stream or inability to fully empty the bladder. If a person progresses to full ...
https://en.wikipedia.org/wiki/Cauda_equina_syndrome
Vaginal cystsVaginal cysts
Symptoms include: infection, bladder dysfunction, abdominal pain, vaginal discharge, and urinary incontinence. It is often ... "Benign Neoplasms of the Vagina , GLOWM". www.glowm.com. Retrieved 2018-03-01. Jaya Prakash, Sheela; M, Lakshmi devi; G, Sampath ... Vaginal cysts can also be congenital and associated with urinary system anomalies The most common type of vaginal cyst are ... large enough to cause urinary incontinence but surgical removal provides treatment and recurrence is unlikely. Diagnosis is ...
https://en.wikipedia.org/wiki/Vaginal_cysts
HydronephrosisHydronephrosis
Lower urinary tract obstruction (such as that caused by bladder outflow obstruction secondary to prostatic hypertrophy) is ... In older adults, the most common cause of hydronephrosis is benign prostate hyperplasia (BPH), or intrapelvic neoplasms such as ... Common causes include bladder dysfunction (such as neurogenic bladder) and urethral obstruction (such as posterior urethral ... Acute obstruction of the upper urinary tract is usually treated by the insertion of a nephrostomy tube. Chronic upper urinary ...
https://en.wikipedia.org/wiki/Hydronephrosis
Sarcoma botryoidesSarcoma botryoides
... urinary bladder of infants and young children or the vagina in females, typically younger than age 8. The name comes from the ... Neoplasms of the Vulva and Vagina. in Holland-Frei Cancer Medicine - 6th Ed. Kufe, DW et al. editors. BC Decker Inc., Hamilton ...
https://en.wikipedia.org/wiki/Sarcoma_botryoides
Transitional epitheliumTransitional epithelium
... lines the organs of the urinary system and is known here as urothelium. The bladder for example has a ... Papillary urothelial lesions Papillary urothelial hyperplasia Urothelial papilloma Papillary urothelial neoplasm of low ... a type of painful bladder syndrome is a chronic disease of the bladder that causes feelings of pressure and pain in the bladder ... Patients with advanced bladder cancer or disease, also often look to bladder reconstruction as a treatment. Current methods of ...
https://en.wikipedia.org/wiki/Transitional_epithelium
FET protein familyFET protein family
"Primary round cell sarcomas of the urinary bladder with EWSR1 rearrangement: a multi-institutional study of thirteen cases with ... EWSR1-SMAD3-positive fibroblastic tumor: These tumors, which are a recently characterized neoplasm with distinct ... Mutation, Genes associated with cancer, RNA-binding proteins, Cancer, Benign neoplasms). ... a wide range of soft tissue neoplasms derived from mesencyhmal tissue cells. Detection of a FET gene-containing fusion gene is ...
https://en.wikipedia.org/wiki/FET_protein_family
Urachal cancerUrachal cancer
It can involve the urinary bladder, but is not bladder cancer in the usual sense. Urachal cancer can occur at any site along ... "Updates in the Pathologic Diagnosis and Classification of Epithelial Neoplasms of Urachal Origin". Advances in Anatomic ... No findings of cystitis glandularis on the bladder surface. These findings can be precursor lesions of a primary bladder ... "The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours". ...
https://en.wikipedia.org/wiki/Urachal_cancer
Inverted papillomaInverted papilloma
It may occur in the nose and/or sinuses or in the urinary tract (bladder, renal pelvis, ureter, urethra). When it occurs in the ... Benign neoplasms, Nose disorders, Urological neoplasia, All stub articles, Oncology stubs). ... Histopathology representing an inverted papilloma of the urinary bladder that was cystoscopically resected. Hematoxylin and ... Histopathology representing an inverted papilloma of the urinary bladder that was cystoscopically resected. Hematoxylin and ...
https://en.wikipedia.org/wiki/Inverted_papilloma
Seminal vesiclesSeminal vesicles
The seminal vesicles are a pair of glands in males that are positioned below the urinary bladder and at the end of the vasa ... Even rarer neoplasms include sarcoma, squamous cell carcinoma, yolk sac tumor, neuroendocrine carcinoma, paraganglioma, ... They lie in the space between the bladder and the rectum; the bladder and prostate lie in front, the tip of the ureter as it ... The Urinary Bladder" Anatomy photo:44:08-0103 at the SUNY Downstate Medical Center - "The Male Pelvis: Structures Located ...
https://en.wikipedia.org/wiki/Seminal_vesicles
Pseudomyxoma peritoneiPseudomyxoma peritonei
... urinary bladder, lung, breast, fallopian tubes, and the pancreas. This disease is often discovered during surgery for other ... For example, neoplasms characterized by high-grade features, invasive glands and or signet ring cells, are termed ... Young RH (May 2004). "Pseudomyxoma peritonei and selected other aspects of the spread of appendiceal neoplasms". Seminars in ... ISBN 978-0-323-35909-2. Sugarbaker PH (January 2006). "New standard of care for appendiceal epithelial neoplasms and ...
https://en.wikipedia.org/wiki/Pseudomyxoma_peritonei
Prostate cancerProstate cancer
Cystoscopy shows the urinary tract from inside the bladder, using a thin, flexible camera tube inserted in the urethra. ... "Male Genitals - Prostate Neoplasms". Pathology study images. University of Virginia School of Medicine. Archived from the ... The prostate surrounds the urethra, a muscular tube that closes the urinary bladder. Any of the mentioned reasons can lead to ... Samuel David Gross (1851). A Practical Treatise On the Diseases and Injuries of the Urinary Bladder, the Prostate Gland, and ...
https://en.wikipedia.org/wiki/Prostate_cancer
Proton therapyProton therapy
Some published studies found a reduction in long term rectal and genito-urinary damage when treating with protons rather than ... Two prominent examples are pediatric neoplasms (such as medulloblastoma) and prostate cancer. Irreversible long-term side ... gastrointestinal and bladder side effects. Proton therapy for eye tumors is a special case since this treatment requires only ... bladder and other tissues anterior to the vertebrae is eliminated, hence a reduction of acute thoracic, ...
https://en.wikipedia.org/wiki/Proton_therapy
Interventional radiologyInterventional radiology
Kidney stones can be present along any part of the course of the urinary tract from the kidneys to the urethra. The most common ... which can result in loss of blood flow to surrounding areas of the bladder or rectum. Data suggests that TURP may have higher ... such as osteoporosis or underlying neoplasm. Analogous to vertebroplasty, the purpose of sacroplasty is to provide ... However, TURP can lead to urinary incontinence or permanent male infertility and may not be the ideal procedure for a certain ...
https://en.wikipedia.org/wiki/Interventional_radiology
ChemotherapyChemotherapy
... as several antineoplastic drugs are known to cause bladder damage. Urinary mutagenicity is a marker of exposure to ... Survivors of childhood cancer are more than 13 times as likely to get a secondary neoplasm during the 30 years after treatment ... Biomarkers of exposure to antineoplastic drugs commonly include urinary platinum, methotrexate, urinary cyclophosphamide and ... The most common secondary neoplasm is secondary acute myeloid leukemia, which develops primarily after treatment with ...
https://en.wikipedia.org/wiki/Chemotherapy
Fibroblast growth factor receptor 1Fibroblast growth factor receptor 1
Acquired abnormalities if the FGFR1 gene are found in: ~14% of urinary bladder Transitional cell carcinomas (almost all are ... These neoplasms were initially regarded as eosinophilias, hypereosinophilias, Myeloid leukemias, myeloproliferative neoplasms, ... Unlike many other myeloid neoplasms with eosinophil such as those caused by Platelet-derived growth factor receptor A or ...
https://en.wikipedia.org/wiki/Fibroblast_growth_factor_receptor_1
PAX8PAX8
PAX gene deficiencies can result in development defects called Congenital Anomalies of the Kidney and Urinary Tract (CAKUT). ... aka Hurthle-Cell Neoplasms). Expression of PAX8 is increased in neoplastic renal tissues, Wilms tumors, ovarian cancer and ... bladder, prostate, and endometrial carcinomas. Expression of PAX8 is also induced during the development of cervical cancer. ...
https://en.wikipedia.org/wiki/PAX8
List of MeSH codes (C23)List of MeSH codes (C23)
... urinary calculi MeSH C23.300.175.850.300 - bladder calculi MeSH C23.300.175.850.550 - kidney calculi MeSH C23.300.175.850.750 ... neoplasm seeding MeSH C23.550.727.650.895 - neoplasms, unknown primary MeSH C23.550.727.655 - neoplasm recurrence, local MeSH ... urinary fistula MeSH C23.300.575.825.250 - bladder fistula MeSH C23.300.575.825.250.775 - vesicovaginal fistula MeSH C23.300. ... neoplasm metastasis MeSH C23.550.727.650.560 - lymphatic metastasis MeSH C23.550.727.650.645 - neoplasm circulating cells MeSH ...
https://en.wikipedia.org/wiki/List_of_MeSH_codes_(C23)
MAGEA4MAGEA4
August 2002). "Prognostic relevance of MAGE-A4 tumor antigen expression in transitional cell carcinoma of the urinary bladder: ... "Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms". Clinical Cancer Research. 9 (17): ...
https://en.wikipedia.org/wiki/MAGEA4
Adjuvant therapyAdjuvant therapy
"Optimal Timing of Chemotherapy and Surgery in Patients with Muscle-Invasive Bladder Cancer and Upper Urinary Tract Urothelial ... Depending on what form of treatment is used, adjuvant therapy can have side effects, like all therapy for neoplasms. ... Neoadjuvant platinum-based chemotherapy has been demonstrated to improve OS in advanced bladder cancer, but there exists some ... Vale, C.L. (August 2005). "Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Update of a Systematic Review and Meta-Analysis ...
https://en.wikipedia.org/wiki/Adjuvant_therapy
Renal cell carcinomaRenal cell carcinoma
The dye travels from the blood stream and into the kidneys which in time, passes into the kidneys and bladder. This test is not ... For small exophytic lesions that do not extensively involve the major vessels or urinary collecting system, a partial ... which is an assessment based on the microscopic morphology of a neoplasm with haematoxylin and eosin (H&E staining). This ... is a useful procedure in detecting the presence of abnormal renal mass in the urinary tract. This procedure involves the ...
https://en.wikipedia.org/wiki/Renal_cell_carcinoma
Smooth muscleSmooth muscle
This ability to stretch and still maintain contractility is important in organs like the intestines and urinary bladder. Smooth ... Intravascular leiomyomatosis is a benign neoplasm that extends through the veins; angioleiomyoma is a benign neoplasm of the ... Smooth muscle is found in the walls of hollow organs, including the stomach, intestines, bladder and uterus; in the walls of ... The reproductive, digestive, respiratory, and urinary tracts, skin, eye, and vasculature all contain this tonic muscle type. ...
https://en.wikipedia.org/wiki/Smooth_muscle
ParagangliomaParaganglioma
"Malignant paraganglioma of the urinary bladder in a 44-year-old female: clinicopathological and immunohistochemical study of a ... A paraganglioma is a rare neuroendocrine neoplasm that may develop at various body sites (including the head, neck, thorax and ... as well as the bladder in extremely rare cases. Paragangliomas originate from paraganglia in chromaffin-negative glomus cells ...
https://en.wikipedia.org/wiki/Paraganglioma
Glossary of medicineGlossary of medicine
Urinary bladder - The urinary bladder, or simply bladder, is a hollow muscular organ in humans and other vertebrates that ... Papillary - In oncology, papillary refers to neoplasms with projections ("papillae", from Latin, 'nipple') that have ... Urinary system - The urinary system, also known as the renal system or urinary tract, consists of the kidneys, ureters, bladder ... Bladder cancer - is any of several types of cancer arising from the tissues of the urinary bladder. It is a disease in which ...
https://en.wikipedia.org/wiki/Glossary_of_medicine
List of MeSH codes (C12)List of MeSH codes (C12)
... urologic neoplasms MeSH C12.740.800.820.125 - bladder neoplasms MeSH C12.740.800.820.750 - kidney neoplasms MeSH C12.740. ... urinary incontinence MeSH C12.777.934.852.727 - urinary incontinence, stress MeSH C12.777.934.880 - urinary retention The list ... bladder neck obstruction MeSH C12.777.103.312 - bladder neoplasms MeSH C12.777.103.374 - bladder, neurogenic MeSH C12.777. ... MeSH C12.294.260.500 - penile neoplasms MeSH C12.294.260.750 - prostatic neoplasms MeSH C12.294.260.937 - testicular neoplasms ...
https://en.wikipedia.org/wiki/List_of_MeSH_codes_(C12)
Urethral cancerUrethral cancer
Bladder cystoscopy is performed to detect if there is simultaneous bladder cancer. Types of urethral cancer include the most ... The World Health Organization classification of tumours of the urinary system and male genital organs (4th edn) was published ... "Immunochemical and molecular assessment of urothelial neoplasms and aspects of the 2016 World Health Organization ... Risk factors suggested include prolonged irritations of the urethra due to urinary catheterization, chronic inflammation due to ...
https://en.wikipedia.org/wiki/Urethral_cancer
Ver por tema Urinary Bladder NeoplasmsVer por tema "Urinary Bladder Neoplasms"
Background: Urinary bladder cancer is the fourth most common cancer in Jordan. No research on survival from bladder cancer at ... Survival of patients with urinary bladder cancer in Jordan, 2005-2014  Nour Abdo; Majd Alsoukhni; Anwar Batieha; Kamal Arqoub ... Histological typing of urinary bladder tumours / F. K. Mostofi, in collaboration with L. H. Sobin, H. Torloni and pathologists ... The epidemiological association between Schistosoma haematobium infection and bladder cancer / by M. C. Pike  ...
https://extranet.who.int/iris/restricted/browse?locale-attribute=pt&type=mesh&authority=Urinary+Bladder+Neoplasms
Pathology of Urinary Bladder Squamous Cell Carcinoma: Overview of Squamous Cell Bladder Carcinoma, Epidemiology of Squamous...Pathology of Urinary Bladder Squamous Cell Carcinoma: Overview of Squamous Cell Bladder Carcinoma, Epidemiology of Squamous...
Squamous cell carcinoma of the bladder is essentially similar to the tumors arising in other organs. ... Squamous cell carcinoma of the urinary bladder is a malignant neoplasm derived from bladder urothelium with pure squamous ... Overview of Squamous Cell Bladder Carcinoma. Squamous cell carcinoma of the urinary bladder is a malignant neoplasm derived ... encoded search term (Pathology of Urinary Bladder Squamous Cell Carcinoma) and Pathology of Urinary Bladder Squamous Cell ...
https://www.medscape.com/answers/1611983-188502/what-are-the-prognosis-and-predictive-factors-of-squamous-cell-carcinoma-of-the-urinary-bladder
Regulations - WTC Health ProgramRegulations - WTC Health Program
Malignant neoplasm of the urinary bladder.. * Malignant neoplasm of the kidney.. * Malignant neoplasms of the renal pelvis; ... Malignant neoplasm of the thyroid.. * Malignant neoplasms of the blood and lymphoid tissues (including, but not limited to, ... Malignant neoplasms of the liver and intrahepatic bile duct.. * Malignant neoplasms of the retroperitoneum and peritoneum; ... Malignant neoplasms of the trachea; bronchus and lung; heart, mediastinum and pleura; and other ill-defined sites in the ...
http://www.cdc.gov/wtc/regulations2.html
Bladder Cancer | Bladder Cancer Symptoms | MedlinePlusBladder Cancer | Bladder Cancer Symptoms | MedlinePlus
Bladder cancer symptoms range from lower back pain to blood in your urine. Read about important risk factors and find a list of ... ClinicalTrials.gov: Urethral Neoplasms (National Institutes of Health) * ClinicalTrials.gov: Urinary Bladder Neoplasms ( ... The bladder is a hollow organ in your lower abdomen that stores urine. Bladder cancer occurs in the lining of the bladder. It ... What Is Bladder Cancer? (National Cancer Institute) Also in Spanish * What Is Bladder Cancer? (American Cancer Society) Also in ...
https://medlineplus.gov/bladdercancer.html
Просмотр по темеПросмотр по теме
Urinary Bladder Neoplasms [‎7]‎. Urinary Tract Infections [‎9]‎. Urogenital Diseases [‎2]‎. Urokinase-Type Plasminogen ...
https://apps.who.int/iris/browse?locale-attribute=ru&etal=-1&type=mesh&starts_with_previous=T&starts_with=U&rpp=20&order=ASC&sort_by=-1
Evaluation of MicroRNA-99a and MicroRNA-205 Expression Levels in Bladder CancerEvaluation of MicroRNA-99a and MicroRNA-205 Expression Levels in Bladder Cancer
Epigenetic changes, such as microRNA alteration are involved in bladder cancer tumorigenesis through a variety of signaling ... Bladder cancer is the second most common cancer in the genitourinary tract, showing often recurrence and progress into invasive ... Keywords: microRNAs; neoplasms; urinary bladder. ... Bladder cancer is the second most common cancer in the ... Dramatic down-regulation of miR-99a in bladder cancer tissues confirmed the tumor suppressor role of miR-99a in bladder cancer ...
https://pubmed.ncbi.nlm.nih.gov/28890885/
Staging and reporting of urothelial carcinoma of the urinary bladder | Modern PathologyStaging and reporting of urothelial carcinoma of the urinary bladder | Modern Pathology
It is now recognized that superficial bladder carcinomas are a heterogenous group of tumors with diverse biological and ... Recognition of diagnostic pitfalls associated with lamina propria invasion is critical for the evaluation of bladder tumor ... This review will discuss recent progress and controversial issues on the staging and substaging of bladder carcinomas. ... Essential elements for handling and reporting of bladder tumor specimens will also be discussed. ...
https://www.nature.com/articles/modpathol20091?error=cookies_not_supported&code=02d01871-d99e-426b-aaa2-39d452336f4e
NIOSHTIC-2 Search Results - Full View
... lung neoplasms; mineral oil; nitrosamines; polycyclic hydrocarbons; aromatic; urinary bladder neoplasms ... Airborne-particles; Automotive-industry; Biohazards; Biological-monitoring; Biological-systems; Bladder-cancer; Bladder-disease ... Increased bladder cancer risk was associated with straight MWFs but not with any other exposure. The hazard ratio increased ... Occupations with mineral oil exposure have been associated with bladder cancer in population-based case-control studies. The ...
http://www2a.cdc.gov/nioshtic-2/BuildQyr.asp?s1=respiratory&f1=%2A&Startyear=&Adv=0&terms=1&EndYear=&Limit=10000&sort=&D1=10&PageNo=346&RecNo=3456&View=f&
Phase II Gemcitabine + Cisplatin +/- Iressa Bladder CCT - Full Text View - ClinicalTrials.govPhase II Gemcitabine + Cisplatin +/- Iressa Bladder CCT - Full Text View - ClinicalTrials.gov
Urinary Bladder Neoplasms. Urologic Neoplasms. Urogenital Neoplasms. Neoplasms by Site. Neoplasms. Urinary Bladder Diseases. ... Phase II Gemcitabine + Cisplatin +/- Iressa Bladder CCT. The safety and scientific validity of this study is the responsibility ... MedlinePlus Genetics related topics: Bladder cancer Drug Information available for: Cisplatin Gemcitabine Gemcitabine ...
https://clinicaltrials.gov/show/NCT00246974
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible...Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible...
Urinary Bladder Neoplasms. Urologic Neoplasms. Urogenital Neoplasms. Neoplasms by Site. Neoplasms. Urinary Bladder Diseases. ... Change From Baseline in Urinary, Bowel and Sexual Domains per Bladder Cancer Index (BCI) [ Time Frame: Baseline, Up to ... TTD in the Urinary, Bowel and Sexual Domains per BCI [ Time Frame: Up to approximately 5 years ]. The 36-item BCI contains 3 ... Muscle Invasive Bladder Cancer Biological: Pembrolizumab Biological: Enfortumab vedotin (EV) Procedure: RC + PLND Drug: ...
https://www.clinicaltrials.gov/ct2/show/NCT04700124
DeCS 2007 - Changed termsDeCS 2007 - Changed terms
C04 - Neoplasms. Bladder Neoplasms. Urinary Bladder Neoplasms. C05 - Musculoskeletal Diseases. Diaphyseal Dysplasia, ...
https://decs.bvs.br/I/rep_i2007.htm
National Ambulatory Medical Care Survey, 1997National Ambulatory Medical Care Survey, 1997
2125.0 Cancer, urinary and male genital tract Includes: Bladder Kidney Prostate. 2130.0 Other malignant neoplasms Includes: ... Neurogenic bladder Excludes: Bladder infection (1665.2) Kidney infection, NOS (1670.2) Passed stones (1680.0) Urinary tract ... 2700.0 Cystitis Excludes: Bladder infection (1665.2) 2705.0 Urinary tract disease except cystitis Includes: Urethritis ... 1680.0 Other symptoms referable to urinary tract Includes: Passed stones Excludes: Kidney stones or bladder stones (2705.0). ...
https://wonder.cdc.gov/wonder/sci_data/surveys/namcs/type_txt/namcs97.asp
Pathology of Inflammatory Myofibroblastic Bladder Tumor: Definition, Epidemiology, Clinical Features and ImagingPathology of Inflammatory Myofibroblastic Bladder Tumor: Definition, Epidemiology, Clinical Features and Imaging
This lesion has been described in numerous locations in addition to the urinary bladder. ... Most benign spindle cell tumors of the urinary bladder are an inflammatory myofibroblastic tumor (IMT). ... differential diagnosis and outcome in thirty-eight spindle cell neoplasms. Mod Pathol. 2001 Oct. 14(10):1043-51. [QxMD MEDLINE ... Most benign spindle cell tumors of the urinary bladder are an inflammatory myofibroblastic tumor (IMT). [1, 2, 3] Although the ...
http://emedicine.medscape.com/article/1611739-overview
High-Dose Multivitamins Compared to a Placebo in Preventing the Recurrence of Cancer in Patients With Early Stage Bladder CancerHigh-Dose Multivitamins Compared to a Placebo in Preventing the Recurrence of Cancer in Patients With Early Stage Bladder Cancer
recurrent bladder cancer. *Urinary Bladder Neoplasms. *Carcinoma, Transitional Cell. .map{width:100%;height:300px;margin-bottom ... Megadose Vitamins as Chemoprevention of Transitional Cell Carcinoma of the Bladder. Trial Phase:. Phase 3. Minimum Age:. 18 ... and I (Ta, T1, and Tis) transitional cell carcinoma of the bladder.. OUTLINE: This is a randomized, double blind study. ... Megadose Vitamins as Chemoprevention of Transitional Cell Carcinoma of the Bladder. OBJECTIVES: I. Determine whether high dose ...
http://www.knowcancer.com/cancer-trials/NCT00003623/
William Martin-Doyle, M.D. | Harvard Catalyst Profiles | Harvard CatalystWilliam Martin-Doyle, M.D. | Harvard Catalyst Profiles | Harvard Catalyst
Ureteral Neoplasms. Neoadjuvant Therapy. Cystectomy. Antineoplastic Agents. Urinary Bladder Neoplasms. Urinary Tract. Aortic ...
https://connects.catalyst.harvard.edu/Profiles/display/person/106836/network/researchareas/timeline
Bladder Cancer - Volume 3, issue 4 - Journals - IOS PressBladder Cancer - Volume 3, issue 4 - Journals - IOS Press
Keywords: Urinary bladder neoplasms, bladder, docetaxel, gemcitabine DOI: 10.3233/BLC-170126 Citation: Bladder Cancer, vol. 3, ... Abstract: Background: Bladder-sparing treatment of muscle invasive bladder cancer (MIBC) with systemic chemotherapy plus ... pathobiology and pharmacology of tumors of the bladder and upper urinary tract with the objective of improving diagnosis, ... and muscle invasive bladder cancers (MIBC). Methods: The study cohort consisted of transurethral bladder resection tumour ( ...
https://content.iospress.com/journals/bladder-cancer/3/4?rows=50
Definition of BCG Failure in Non-Muscle Invasive Bladder Cancer in Major Urological GuidelinesDefinition of BCG Failure in Non-Muscle Invasive Bladder Cancer in Major Urological Guidelines
Transitional cell neoplasms of the urinary bladder. Can biologic potential be predicted from histologic grading? Cancer. . 1987 ... neoplasms of the urinary bladder. Am J Surg Pathol. . 1998;22:1435-1448. ... T1 Urothelial carcinoma of the Bladder. In: Soloway M, Carmac A, Khoory A, eds. Bladder Tumors. . Paris, France. Health ... Bladder cancer (BC) is the fifth most commonly diagnosed cancer in the nation. It is estimated that 70 980 men and women will ...
https://www.urotoday.com/volume-4-2011/vol-4-issue-6/48720-definition-of-bcg-failure-in-non-muscle-invasive-bladder-cancer-in-major-urological-guidelines.html
Medical Microbiology<...Medical Microbiology<...
Urinary Bladder Neoplasms 58% * Intravesical 57% * Colonic Neoplasms 55% 15 Citations (SciVal) ... A bacterial protease depletes c-MYC and increases survival in mouse models of bladder and colon cancer. Butler, D. S. C., ...
https://portal.research.lu.se/en/organisations/medical-microbiology
Exploring the Pathological Mechanism of Bladder Cancer Based on Tumor Mutational Burden AnalysisExploring the Pathological Mechanism of Bladder Cancer Based on Tumor Mutational Burden Analysis
... some key genes have been discovered to drive the development and prognosis of urinary bladder neoplasm. On account of the ... this study is supposed to provide new therapies for the treatment of bladder neoplasm. ... New therapeutic targets are eager to be discovered to improve the outcomes of bladder cancer. With the development of high- ... Based on the understanding of the bladder tumor genome and immune environment, ...
https://www.hindawi.com/journals/bmri/2019/1093815/
Carcinogens Summary Report | CureHunterCarcinogens Summary Report | CureHunter
Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are ... Substances that increase the risk of NEOPLASMS in humans or animals. ... Urinary Bladder Neoplasms (Bladder Cancer) 01/01/2012 - "Many epidemiological and experimental studies report a strong role of ... Lung Neoplasms (Lung Cancer) 12/01/2009 - "The best protection against lung cancer is avoidance of airborne carcinogens and ...
https://www.curehunter.com/public/keywordSummaryD002273.do
Publication Year: 2019 / Subject: antineoplastic activity / Subject term: antioxidant activity - PubAg Search ResultsPublication Year: 2019 / Subject: antineoplastic activity / Subject term: antioxidant activity - PubAg Search Results
... urinary bladder neoplasms. Abstract:. ... In this work the polymerization of catechin, epicatechin, and resveratrol was carried ... neoplasm cells; oils; reactive oxygen species; uterine cervical neoplasms; India. Abstract:. ... The present study aimed to ... neoplasm cells; neoplasms; oxidative stress; toxicity. Abstract:. ... The present study aimed to determine the chemical ... neoplasm cells; neoplasms; oils; pathogens; phenols; toxicity testing. Abstract:. ... BACKGROUND: There is increasing interest ...
https://pubag.nal.usda.gov/?f%5Bpublication_year_rev_facet%5D%5B%5D=7981-2019&f%5Bsubject_facet%5D%5B%5D=antineoplastic+activity&f%5Bsubject_term%5D%5B%5D=antioxidant+activity&per_page=50&sort=date-asc
BT8009-100 in Subjects With Nectin-4 Expressing Advanced Solid Tumors Malignancies - Bladder Cancer Advocacy NetworkBT8009-100 in Subjects With Nectin-4 Expressing Advanced Solid Tumors Malignancies - Bladder Cancer Advocacy Network
Urinary Bladder Neoplasm. * Triple Negative Breast Neoplasms. * Carcinoma. * Non-Small-Cell Lung ... Read Johns Bladder Cancer Story: "When is this Going to be Over?" ... Copyright © 2017-2022 Bladder Cancer Advocacy Network. BCAN is a 501(c)3 non-profit organization. ... By submitting this form, you are consenting to receive marketing emails from: Bladder Cancer Advocacy Network, 4520 East West ...
https://bcan.org/clinicaltrials/bt8009-100-in-subjects-with-nectin-4-expressing-advanced-solid-tumors-malignancies/
Nuclear p53 expression is associated with allelic imbalance (TP53) in glandular dysplasia and typical cystitis glandularis: a...
Urinary Bladder Neoplasms, Cystitis, Cell Nucleus, Intestinal Mucosa, Urinary Bladder, Allelic Imbalance, Loss of ...
https://pure.qub.ac.uk/en/publications/nuclear-p53-expression-is-associated-with-allelic-imbalance-tp53-
DailyMed - GLATOPA- glatiramer acetate injection, solutionDailyMed - GLATOPA- glatiramer acetate injection, solution
... bladder carcinoma; urinary frequency ... benign skin neoplasm, skin carcinoma, skin striae, and ... Nervous System: myelitis; meningitis; CNS neoplasm; cerebrovascular accident; brain edema; abnormal dreams; aphasia; convulsion ... Urogenital System: urogenital neoplasm; urine abnormality; ovarian carcinoma; nephrosis; kidney failure; breast carcinoma; ... Frequent: Amenorrhea, hematuria, impotence, menorrhagia, suspicious papanicolaou smear, urinary frequency, and vaginal ...
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5f01e40a-b6f6-40fb-b37c-3d06f1428e86&audience=consumer
Dermatology - Research output - Experts@MinnesotaDermatology - Research output - [email protected]
Second Primary Neoplasms 88% * Hodgkin Disease 79% * Urinary Bladder Neoplasms 74% * Non-Hodgkins Lymphoma 72% ... Paraneoplastic Signs in Bladder Transitional Cell Carcinoma: An Unusual Presentation. Schlarbaum, J. P., Fenyk, J., Miller, D. ... Cutaneous T-cell lymphoma is associated with increased risk of lymphoma, melanoma, lung cancer, and bladder cancer. Goyal, A., ... Screening for second malignancies in mycosis fungoides: non-Hodgkin lymphoma, Hodgkin lymphoma, lung cancer, bladder cancer and ...
https://experts.umn.edu/en/organisations/dermatology/publications/?ordering=publicationYearThenTitle&descending=false&page=24
The combination of an mTORc1/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro - Fingerprint - Mayo...
Urinary Bladder Neoplasms 46% * PP242 35% * Cell Proliferation 31% * Cell Line 28% ... Dive into the research topics of The combination of an mTORc1/TORc2 inhibitor with lapatinib is synergistic in bladder cancer ... The combination of an mTORc1/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro. ...
https://mayoclinic.pure.elsevier.com/en/publications/the-combination-of-an-mtorc1torc2-inhibitor-with-lapatinib-is-syn/fingerprints/
Candida of the bladder wall: Computerized tomography demonstration<...
Urinary Bladder Medicine & Life Sciences 78% * Vulvar Neoplasms Medicine & Life Sciences 68% ... Candida of the bladder wall : Computerized tomography demonstration. / Trinh, T. D.; Gatewood, O. M.B.; Fishman, E. K. ... Trinh, T. D. ; Gatewood, O. M.B. ; Fishman, E. K. / Candida of the bladder wall : Computerized tomography demonstration. In: ... Candida of the bladder wall: Computerized tomography demonstration. Journal of Urology. 1986 Jan 1;135(5):1008-1009. doi: ...
https://jhu.pure.elsevier.com/en/publications/candida-of-the-bladder-wall-computerized-tomography-demonstration-4
HuGE Navigator|Genopedia|PHGKBHuGE Navigator|Genopedia|PHGKB
Ovarian Neoplasms 1 0 Pulmonary Disease, Chronic Obstructive 1 0 Urinary Bladder Neoplasms 1 0 ... Colorectal Neoplasms 1 0 Note: The number of publications displayed in this table will differ from the number displayed in the ...
https://phgkb.cdc.gov/PHGKB/huGEPedia.action?firstQuery=ATP1B2&geneID=482&typeSubmit=GO&check=y&typeOption=gene&which=2&pubOrderType=pubD
Kyoto University Research Information Repository: SearchKyoto University Research Information Repository: Search
1 Prostatic Neoplasms. *1 Pyelonephritis. *1 Solvents. *1 Urinary Bladder Neoplasms. *1 Urinary Calculi ...
https://repository.kulib.kyoto-u.ac.jp/dspace/handle/2433/111243/simple-search?filterquery=1963&filtername=dateIssued&filtertype=equals
Dr. Robert Abouassaly, MD | Fairview Park, OH | Urologist | VitalsDr. Robert Abouassaly, MD | Fairview Park, OH | Urologist | Vitals
Bladder Issues * Prostate Cancer (Prostatic Neoplasm) * Erectile Dysfunction (ED) * Prostatitis * Urinary Bladder Cancer ...
https://www.vitals.com/doctors/Dr_Robert_Abouassaly_2.html
CancerTumorTumorsMetastasisCystectomyUrothelialCancersHistologicalHematuriaRenalRecurrenceCarcinoma of the urinaryHumansKidneyMetastaticCarcinomasRecurrentPrimaryBenign prostatic hClinicalIncidenceDiagnosisSquamous cellAntineoplasticRadiotherapyDysplasiaLesionPatients
Cancer81
  • Background: Urinary bladder cancer is the fourth most common cancer in Jordan. (who.int)
  • No research on survival from bladder cancer at the national level has been conducted before. (who.int)
  • For more information, see Bladder Cancer . (medscape.com)
  • Bladder cancer is the second most common cancer in the genitourinary tract, showing often recurrence and progress into invasive states. (nih.gov)
  • Epigenetic changes, such as microRNA alteration are involved in bladder cancer tumorigenesis through a variety of signaling pathways. (nih.gov)
  • 36 patients with bladder cancer were included in the study. (nih.gov)
  • Dramatic down-regulation of miR-99a in bladder cancer tissues confirmed the tumor suppressor role of miR-99a in bladder cancer. (nih.gov)
  • A higher amount of miR-99a expression was associated with invasive bladder cancer. (nih.gov)
  • Bladder cancer is a significant cause of cancer morbidity and mortality, accounting for an estimated 68 810 new cases and 14 100 cancer deaths in the United States in 2008. (nature.com)
  • Historically, the term 'superficial bladder cancer' has been used to describe tumors that have not invaded into muscularis propria. (nature.com)
  • Quantitative exposure to metalworking fluids and bladder cancer incidence in a cohort of autoworkers. (cdc.gov)
  • Occupations with mineral oil exposure have been associated with bladder cancer in population-based case-control studies. (cdc.gov)
  • The authors report results from the first cohort study to examine bladder cancer incidence in relation to quantitative exposures to metalworking fluids (MWFs), based on 21,999 male Michigan automotive workers, followed from 1985 through 2004. (cdc.gov)
  • Increased bladder cancer risk was associated with straight MWFs but not with any other exposure. (cdc.gov)
  • Bladder Cancer i s an international multidisciplinary journal aiming to facilitate progress in understanding the epidemiology, etiology, molecular genetics, pathogenesis, pathobiology and pharmacology of tumors of the bladder and upper urinary tract with the objective of improving diagnosis, treatment and survivorship in patients. (iospress.com)
  • To date, there is no convincing evidence that, in the hands of equally experienced surgeons who treat bladder cancer routinely, a skillfully performed RARC is less oncologically efficacious than a skillfully performed ORC. (iospress.com)
  • Background: It is a critical unmet need to predict chemosensitivity in muscle-invasive bladder cancer patients who receive neoadjuvant chemotherapy (NAC). (iospress.com)
  • Materials and Methods: Twenty patients with pT2 bladder cancer have … been included in this study. (iospress.com)
  • Bladder cancer (BC) is the fifth most commonly diagnosed cancer in the nation. (urotoday.com)
  • Radical cystectomy (RC) is the most effective treatment for locally advanced bladder cancer and is a formidable operation. (urotoday.com)
  • As of January 1, 2004, approximately 51 1790 individuals in the US have bladder cancer [1,2]. (urotoday.com)
  • Thus, individuals who have high-grade bladder cancer are at a significant risk, whereas those with low grade are unlikely to die of this cancer. (urotoday.com)
  • Since its introduction in 1976 by Morales, intravesical BCG has played an important role in the management of high-grade, non-muscle-invasive bladder cancer (NMIBC). (urotoday.com)
  • For HG T1 bladder cancer (tumor invasion of lamina propria), the recurrence and progression rates are 42 and 23%, respectively, with a 14% delayed cystectomy rate [8]. (urotoday.com)
  • Although immunotherapy has progressed in the treatment of bladder cancer, some patients still have poor prognosis. (hindawi.com)
  • New therapeutic targets are eager to be discovered to improve the outcomes of bladder cancer. (hindawi.com)
  • Through the interpretation of related data from the Cancer Genome Atlas database (TCGA), some key genes have been discovered to drive the development and prognosis of urinary bladder neoplasm. (hindawi.com)
  • On account of the success of immunotherapy in many cancer types, we established the relationship between tumor mutation burden and immune microenvironment of bladder cancer and found the changes of several immune cells in this disease. (hindawi.com)
  • Bladder cancer is a major malignant tumor with a high incidence in the urinary system. (hindawi.com)
  • According to the clinical staging criteria, nonmuscle invasive bladder cancer, muscle invasive bladder cancer, and metastatic urothelial carcinoma have different treatment methods and therapeutic effects. (hindawi.com)
  • Primary noninvasive bladder cancer can be remedied by transurethral resection or intravesical injection [ 4 , 5 ]. (hindawi.com)
  • It is exciting to note that immunological checkpoint inhibitors are increasingly being utilized to treat refractory or non-platinum-compliant bladder cancer and have improved the treatment prospects for this disease [ 10 ]. (hindawi.com)
  • Tumors such as non-small-cell lung cancer, melanoma, and bladder tumor with high TMB often produce new antigens leading to enrichment of immune cells. (hindawi.com)
  • found the activity of Bacillus Calmette-Guerin in the treatment of nonmuscle invasive bladder cancer, which has been called immunoreactive tumors [ 19 , 20 ]. (hindawi.com)
  • At last, the relationship between TMB and patient survival in bladder cancer was constructed. (hindawi.com)
  • We describe a patient with a history of vulvar cancer, aplastic anemia and diabetes who was found to have a bladder wall lesion on a computerized tomography scan, which was compatible with malignancy. (elsevier.com)
  • Eligible patients had unresectable bladder cancer, previously treated with one line of systemic chemotherapy. (elsevier.com)
  • 1. Nielsen M, Qaseem A. Hematuria as a marker of occult urinary tract cancer: advice for high-value care from the American College of Physicians. (bmj.com)
  • Purpose: To evaluate the pattern of care in patients with high risk non muscle invasive bladder cancer (NMIBC) in the Comprehensive Cancer Center North-Netherlands (CCCN) and to assess factors associated with the choice of treatment, recurrence and progression free survival rates. (rug.nl)
  • abstract = "Purpose: To evaluate the pattern of care in patients with high risk non muscle invasive bladder cancer (NMIBC) in the Comprehensive Cancer Center North-Netherlands (CCCN) and to assess factors associated with the choice of treatment, recurrence and progression free survival rates.Materials and Methods: Retrospective analysis of 412 patients with newly diagnosed high risk NMIBC. (rug.nl)
  • Tumors or cancer of the URINARY BLADDER . (bvsalud.org)
  • Background: Smoking is a major risk factor for bladder cancer (BC). (birmingham.ac.uk)
  • Dose-response meta-analyses showed a BC risk plateau for smoking intensity and indicate that even after long-term smoking cessation, an elevated risk of bladder cancer remains. (birmingham.ac.uk)
  • PURPOSE: To determine the efficacy and safety of a high-dose-rate (HDR) brachytherapy schedule in the treatment of bladder cancer and to investigate the impact of different values of repair half-times and alpha/beta ratios on the design of the HDR schedule. (vumc.nl)
  • CONCLUSION: Local control of HDR brachytherapy for bladder cancer was disappointing and late toxicity unexpectedly high. (vumc.nl)
  • The increase in late toxicity suggested a short repair half-time of 0.5-1 h for late-responding normal bladder tissue, which would not support HDR brachytherapy in the treatment of bladder cancer. (vumc.nl)
  • Data on 482 stage A-0 - D2 bladder cancer patients referred between 1975-86 were analyzed. (bgu.ac.il)
  • Because this cancer has a predilection for the bladder trigone, it is not unusual for dogs to have an unremarkable physical examination. (mspca.org)
  • This commercially available test (Cadet BRAF test) can successfully detect cancer in ~80% of dogs with bladder or prostate cancer. (mspca.org)
  • N-acetyltransferase 2 and bladder cancer: an overview and consideration of the evidence for gene-environment interaction. (ox.ac.uk)
  • This article reviews the results of 21 published case-control studies of NAT2 polymorphism and bladder-cancer risk, with a total of 2700 cases and 3426 controls. (ox.ac.uk)
  • The published evidence suggests that NAT2 slow acetylator phenotype or genotype may be associated with a small increase in bladder cancer risk. (ox.ac.uk)
  • Only five of the 21 studies reported results separately for the effect of NAT2 on bladder cancer risk in smokers and non-smokers. (ox.ac.uk)
  • There was insufficient evidence to assess the joint effect of NAT2 and occupational exposure to arylamines on bladder cancer risk. (ox.ac.uk)
  • Recent investigations have given a clearer insight into the genetic progression of bladder cancer. (springernature.com)
  • In this review we identify the clinical courses of bladder cancer, review the basic concepts of carcinogenesis, and focus on the specific cytogenetic and molecular alterations observed in bladder cancer. (springernature.com)
  • Urinary bladder cancer is a common malignancy in industrialized countries. (elsevier.com)
  • More than 90% of bladder cancer originates in the transitional cells. (elsevier.com)
  • Bladder transitional cancer prognosis is, according to the most recent definition related to the level of tumor infiltration, characterized by two main phenotypes, Non Muscle Invasive Bladder Transitional Cancer (NMIBC) and Muscle Invasive Bladder Transitional Cancer (MIBC). (elsevier.com)
  • It has recently been reported that the chromosomal region 12q13-15, containing crucial cancer genes such as MDM2, CDK4, GLI and an entire cluster of HOX genes, is amplified in bladder cancer. (elsevier.com)
  • In this study we have been investigated, by immunohistochemisty and quantitative Real Time PCR, the HOX B13 expression in bladder cancer evolution and progression, evaluating its ability to discriminate between NMIBC and MBCI phenotypes. (elsevier.com)
  • The de-regulation and delocalization of HOX B13 in urinary bladder cancer supports again the important role of HOX genes in tumor evolution and represents a starting point to establish an integrated analysis, in which HOX genes represent important prognostic and predictive markers for bladder cancer. (elsevier.com)
  • The data presented in this edition of Cancer Incidence in Five The CI5 data include all invasive malignant neoplasms and Continents (CI5) are mainly organised according to anatomical some non-invasive malignant neoplasms For most morphology site However, for some sites, the histological type of cancer codes, a fifth digit /1 or /2 automatically excludes the data entry. (who.int)
  • Other specified malignant neoplasm (Other specified cancer tumour Other codes are obsolete, ie the entities have been in the previous edition). (who.int)
  • In 2019, the US Preventive Services Task Force (USPSTF) concluded that the evidence was insufficient to determine the balance of benefits and harms of screening for bladder cancer in asymptomatic adults. (medscape.com)
  • Although adults with mild lower urinary tract symptoms (eg, urinary frequency, hesitancy, urgency, dysuria, nocturia) are not strictly asymptomatic, these symptoms are common and are not believed to be associated with an increased risk of bladder cancer. (medscape.com)
  • No major organization recommends screening for bladder cancer in asymptomatic adults. (medscape.com)
  • [ 151 ] The American Cancer Society states that prompt attention to bladder symptoms is the best approach for finding bladder cancer in its earliest, most treatable stages in persons with no known risk factors. (medscape.com)
  • Cigarette smoking is the most established risk factor for bladder cancer, increasing relative risk four- to five-fold relative to never smoking for current smokers and two- to three-fold for former smokers. (medscape.com)
  • The European Association of Urology (EAU) guidelines estimate a 40% reduction in the risk of developing bladder cancer within 1-4 years of quitting smoking, increasing to a 60% reduction after 25 years of smoking cessation. (medscape.com)
  • The treatment of non-muscle-invasive (Ta, T1, carcinoma in situ [CIS]) and muscle-invasive bladder cancer should be differentiated. (medscape.com)
  • The two principal treatment choices in muscle-invasive bladder cancer are radical cystectomy and transurethral resection of bladder tumor (TURBT) followed by concurrent radiation therapy and systemic chemotherapy (trimodality therapy). (medscape.com)
  • Chedgy and Black propose that radical cystectomy should be considered the gold-standard treatment for muscle-invasive bladder cancer. (medscape.com)
  • They cite recommendations from European and United States guidelines, as well as published literature showing a 75% 5-year cancer-specific survival for all stages of bladder cancer treated with cystectomy, while noting that the published literature on trimodality therapy shows evidence of inferior survival and frequent treatment failure, with almost one-third of patients eventually requiring a salvage cystectomy. (medscape.com)
  • In contrast, Mitin recommends considering trimodality therapy as the first option for patients with muscle-invasive bladder cancer, with cystectomy reserved for patients who are unable or unwilling to undergo bladder preservation or for salvage in the case of local recurrence. (medscape.com)
  • In the future, treatment selection for muscle-invasive bladder cancer is likely to be based on testing of tumors for biomarkers that indicate treatment sensitivity. (medscape.com)
  • Dietary fats and their sources in association with the risk of bladder cancer: A pooled analysis of 11 prospective cohort studies. (who.int)
  • Molecular Diagnostic and Prognostication Assays for the Subtyping of Urinary Bladder Cancer Are on the Way to Illuminating Our Vision. (who.int)
  • Excess bladder cancer risk was evident among women firefighters. (cdc.gov)
  • However, because bladder cancer is far less likely in women than in men and less than 4% of our study group were women, our results are based on only a few bladder cancer cases. (cdc.gov)
  • Examining cancer incidence (i.e., diagnoses) in addition to deaths from cancer is preferable when assessing risks of cancers that tend to have higher survival rates, such as testicular, bladder, breast, and prostate cancers. (cdc.gov)
Tumor15
  • Because many urothelial carcinomas contain a minor squamous cell component, a diagnosis of squamous cell carcinoma of the bladder should be rendered only when the tumor is solely composed of a squamous cell component in the absence of a conventional urothelial carcinoma component. (medscape.com)
  • The term 'superficial,' therefore, is no longer used for bladder tumor nomenclature. (nature.com)
  • Recognition of diagnostic pitfalls associated with lamina propria invasion is critical for the evaluation of bladder tumor specimens. (nature.com)
  • Essential elements for handling and reporting of bladder tumor specimens will also be discussed. (nature.com)
  • It is now recommended that the term 'superficial' be entirely eliminated from bladder tumor nomenclature. (nature.com)
  • Most benign spindle cell tumors of the urinary bladder are an inflammatory myofibroblastic tumor (IMT). (medscape.com)
  • Microscopic findings of inflammatory myofibroblastic tumor of the bladder. (medscape.com)
  • Quantitative Assessment of Heterogeneity in Bladder Tumor MRI Diffusivity: Can Response be Predicted Prior to Neoadjuvant Chemotherapy? (iospress.com)
  • Many studies have confirmed its value in reducing tumor recurrence following transurethral resection of bladder tumors (TURBT). (urotoday.com)
  • Based on the understanding of the bladder tumor genome and immune environment, this study is supposed to provide new therapies for the treatment of bladder neoplasm. (hindawi.com)
  • Urothelial carcinoma is the most common histopathological type of bladder tumor [ 3 ]. (hindawi.com)
  • First, data related to malignant tumor of urinary bladder in TCGA database were collected and the TMB values were calculated then. (hindawi.com)
  • After then, the microenvironment of bladder tumor was studied and new tumor immunotherapy for the diagnosis and treatment of this disease was explored. (hindawi.com)
  • Objective: The aim of this study was to analyze the stage-specific impact of upper or lower urinary tract tumor location on oncologic outcomes. (elsevier.com)
  • Another commercially available bladder tumor antigen (BTA) test can support a diagnosis of TCC, although false-positive results can be obtained when there is significant proteinuria, glucosuria, pyuria, or hematuria. (mspca.org)
Tumors13
  • [ 7 ] notably Sudan and Egypt, where squamous cell carcinoma ranges from two thirds to three quarters of all malignant tumors of the bladder. (medscape.com)
  • It is now recognized that 'superficial' bladder carcinomas are a heterogenous group of tumors with diverse biological and clinical manifestations. (nature.com)
  • According to the authors, the molecular characteristics and clinical behavior of pediatric bladder tumors are, with the exception of rhabdomyosarcoma, less well understood than those in adults. (medscape.com)
  • [ 11 ] The oldest large series of 38 spindle cell tumors in the urinary bladder included 17 pseudotumors, 4 postoperative spindle cell nodules (PSCNs), and 13 sarcomas. (medscape.com)
  • Objective: The aim of this study is to assess if a quantitative measurement of ADC heterogeneity in bladder tumors can be a predictor of therapeutic response to NAC. (iospress.com)
  • The 37 malignant tumors included lymphomas (eight in patients receiving cyclosporine and four in patients not given cyclosporine) and carcinomas of the skin and lips (11), head and neck (five), colon and rectum (three), uterus (two), vulva (two), lung (one), and urinary bladder (one). (elsevier.com)
  • The neoplasms of the skin, vulva, uterine cervix, and urinary bladder were low-grade malignant tumors. (elsevier.com)
  • Stratifying risk of urinary tract malignant tumors in patients with asymptomatic microscopic hematuria. (bmj.com)
  • Tumors of the bladder and urethra account for approximately 0.5-1.0% of all canine neoplasms. (mspca.org)
  • bladder tumors are malignant, and 75 to 90% of primary urinary bladder epithelial tumors are transitional cell carcinomas (TCC). (mspca.org)
  • While abdominal ultrasonography (AUS) is the most relied upon imaging tool to evaluate the bladder, urethra, and prostate, TCCs can have a wide variety of appearances on abdominal ultrasound, which overlaps those of other tumors, benign polyps, cystitis, and urethritis. (mspca.org)
  • Patients with resistant tumors would be offered upfront cystectomy, while those with chemoradiation-sensitive tumors would be offered bladder-preserving therapy, with regimens selected on the basis of genetic analysis. (medscape.com)
  • However, it is useful in the diagnosis of UUTUC, because it can distinguish between radiolucent renal stones and upper urinary tract urothelial tumors in that stones appear opaque on CT scans. (medscape.com)
Metastasis2
  • Oral Metastasis from a carcinoma of the urinary Bladder is extremely uncommon. (who.int)
  • Two cases of transitional cell carcinoma of the Bladder, presenting eighteen and ten months after initial diagnosis, one with soft tissue metastasis in the upper alveolus and the other with bony metastasis to the mandible are discussed. (who.int)
Cystectomy1
  • Nevertheless, cisplatin-based chemotherapy was first used for muscle-infiltrating urothelial carcinoma before radical cystectomy or the option of bladder preservation [ 6 , 7 ]. (hindawi.com)
Urothelial2
  • It is a gross and microscopic mimicker of urothelial neoplasm or metastatic carcinoma. (duke.edu)
  • Background: Dissimilarities in management and outcomes exist between upper tract urothelial carcinoma (UTUC) and urothelial carcinoma of the bladder (UCB). (elsevier.com)
Cancers4
  • Monoclonality of multiple bladder cancers. (ox.ac.uk)
  • Genetic polymorphism of the carcinogen metabolizing enzyme N-acetyl transferase 2 (NAT2) may influence susceptibility to bladder cancers related to smoking or to occupational exposure to arylamine carcinogens. (ox.ac.uk)
  • L'ACE et le CA19-9 ont une bonne sensibilité et une spécificité relative qui leur permettent de suivre l'évolution des cancers digestifs en particulier les cancers colorectaux. (bvsalud.org)
  • For example, firefighters who were under 65 years of age had more bladder and prostate cancers than expected. (cdc.gov)
Histological1
  • The main structure of the histological grouping is that Morphology codes specific types of malignant neoplasms are listed as wel as Grouping of morphological codes presents several difficulties. (who.int)
Hematuria3
  • The most common presenting symptom is hematuria, followed by bladder outlet obstruction and dysuria. (medscape.com)
  • Most commonly, dogs with undiagnosed TCC will present to your veterinary hospital with lower urinary tract signs indistinguishable from those observed with urolithiasis or lower urinary tract infection and may include stranguria and hematuria pollakiuria, and tenesmus. (mspca.org)
  • Adults with gross hematuria or acute changes in lower urinary tract symptoms were not included in this population. (medscape.com)
Renal3
  • By immunohistochemistry, nephrogenic adenomas are positive for renal epithelial markers CK7, CD10 and alpha-methylacyl-coenzyme A racemase, and negative for bladder urothelium or prostate markers. (duke.edu)
  • Renal insufficiency can be caused, for example, by drugs that damage the kidneys or repeated inflammation of the urinary tract. (krebsdaten.de)
  • Generally, kidney tumours originate from the proliferation of malignant cells within the renal tubules (or nephrons), or they are neoplasms from the fibrous tissues (that cover the organ itself). (lugnani.com)
Recurrence1
  • OBJECTIVES: I. Determine whether high dose multivitamins have chemopreventive efficacy beyond standard therapy in reducing the risk of recurrence in patients with resected stage 0 and I (Ta, T1, and Tis) transitional cell carcinoma of the bladder. (knowcancer.com)
Carcinoma of the urinary2
  • Squamous cell carcinoma of the urinary bladder is a malignant neoplasm derived from bladder urothelium with pure squamous phenotype. (medscape.com)
  • IMSEAR at SEARO: Carcinoma of the urinary bladder metastatic to the oral cavity. (who.int)
Humans1
  • Substances that increase the risk of NEOPLASMS in humans or animals. (curehunter.com)
Kidney1
  • Malignant neoplasms of the kidney can originate from different types of tissue. (krebsdaten.de)
Metastatic1
  • We have carried out a phase II study in advanced or metastatic transitional cell carcinoma of the bladder. (elsevier.com)
Carcinomas4
  • In the United States, squamous cell carcinoma constitutes around 2%-5% of all urinary bladder carcinomas. (medscape.com)
  • In certain parts of the African continent, the majority of bladder carcinomas are of the squamous cell type. (medscape.com)
  • A higher degree of adenocarcinoma has also been reported in schistosomal-associated bladder carcinomas. (medscape.com)
  • This review will discuss recent progress and controversial issues on the staging and substaging of bladder carcinomas. (nature.com)
Recurrent1
  • The history of dogs with prostatic disease entails some combination of the following abnormalities: difficulty defecating, stranguria and dysuria, urinary incontinence, recurrent UTI's, blood or purulent material in the ejaculate, ejaculatory failure, blood in the urine, blood dripping from the penis unassociated with urination, and purulent or hemorrhagic urethral discharge. (dvm360.com)
Primary1
  • Primary conditions affecting the canine prostate include acute prostatitis, chronic prostatitis with or without abscess formation, benign prostatic hyperplasia (BPH), neoplasms of the prostate, squamous metaplasia, prostatic and paraprostatic cysts, and prostatic calculi. (dvm360.com)
Benign prostatic h1
  • Medical and surgical treatment modalities for lower urinary tract symptoms in the male patient secondary to benign prostatic hyperplasia: a review. (bmj.com)
Clinical2
  • Inspired of this work, a novel strategy was composed in this work for clinical treatment by exploring the relationship between TMB and immune cells in bladder neoplasm. (hindawi.com)
  • Radiographic and clinical predictors of bladder rupture in blunt trauma patients with pelvic fracture. (bmj.com)
Incidence2
  • Worldwide, the incidence of squamous cell carcinoma of the bladder varies. (medscape.com)
  • Cyclophosphamide chemotherapy has also been reported to increase the incidence of squamous cell carcinoma of the bladder. (medscape.com)
Diagnosis2
  • Thus, when faced with this diagnosis, there is a desire to pursue a bladder-preserving strategy and avoid RC. (urotoday.com)
  • The differential diagnosis of filling defects in the bladder as seen on computerized tomography is discussed. (elsevier.com)
Squamous cell3
  • Having bladder diverticula may increase the likelihood that an individual will develop squamous cell carcinoma. (medscape.com)
  • [ 14 ] Bladder exstrophy has been associated with the development of squamous cell carcinoma at a younger age than usual. (medscape.com)
  • As previously mentioned, schistosomiasis is the major cause of squamous cell carcinoma of the bladder in African countries. (medscape.com)
Antineoplastic1
  • Use additional code (U85) , if desired, to identify resistance, non-responsiveness and refractive properties of the neoplasm to antineoplastic drugs. (who.int)
Radiotherapy1
  • METHODS AND MATERIALS: Between 2000 and 2002, 40 patients with T1G3 and T2 bladder carcinoma were treated with 30 Gy external beam radiotherapy followed by interstitial HDR brachytherapy to a total dose of 32 Gy in 10 sessions of 3.2-Gy fractions in two fractions daily with a 6-h interfraction interval. (vumc.nl)
Dysplasia1
  • Flat intraurothelial lesions of the urinary bladder-do hyperplasia, dysplasia, and atypia of unknown significance need to exist as diagnostic entities? (nature.com)
Lesion1
  • Nephrogenic adenoma is a benign lesion of the urinary tract, particularly the urinary bladder. (duke.edu)
Patients1
  • In one study from Egypt, 82% of patients with bladder carcinoma were found to harbor Schistosoma haematobium eggs in the bladder wall. (medscape.com)
Ver por tema Urinary Bladder Neoplasms
Ver por tema "Urinary Bladder Neoplasms" (extranet.who.int)
Browsing EMRO Publications by Subject Urinary Bladder Neoplasms
Browsing EMRO Publications by Subject "Urinary Bladder Neoplasms" (extranet.who.int)
Bladder cancer: MedlinePlus Genetics
Bladder cancer: MedlinePlus Genetics (medlineplus.gov)
Browsing EMRO Journal Articles (‎EMHJ)‎ by Subject Urinary Bladder Neoplasms
Browsing EMRO Journal Articles (‎EMHJ)‎ by Subject "Urinary Bladder Neoplasms" (extranet.who.int)
Phase II Gemcitabine + Cisplatin +/- Iressa Bladder CCT - Full Text View - ClinicalTrials.gov
Phase II Gemcitabine + Cisplatin +/- Iressa Bladder CCT - Full Text View - ClinicalTrials.gov (clinicaltrials.gov)
Radical Cystectomy Treatment & Management: Medical Therapy, Surgical Therapy, Preoperative Details
Radical Cystectomy Treatment & Management: Medical Therapy, Surgical Therapy, Preoperative Details (medscape.com)
Pathology of Urinary Bladder Squamous Cell Carcinoma: Overview of Squamous Cell Bladder Carcinoma, Epidemiology of Squamous...
Pathology of Urinary Bladder Squamous Cell Carcinoma: Overview of Squamous Cell Bladder Carcinoma, Epidemiology of Squamous... (medscape.com)
Bladder Cancer | Bladder Cancer Symptoms | MedlinePlus
Bladder Cancer | Bladder Cancer Symptoms | MedlinePlus (medlineplus.gov)
Partial Cystectomy Workup: Laboratory Studies, Imaging Studies, Diagnostic Procedures
Partial Cystectomy Workup: Laboratory Studies, Imaging Studies, Diagnostic Procedures (medscape.com)
Bladder Cancer Treatment & Management: Approach Considerations, Treatment of Non-Muscle-Invasive Disease (Ta, T1, CIS),...
Bladder Cancer Treatment & Management: Approach Considerations, Treatment of Non-Muscle-Invasive Disease (Ta, T1, CIS),... (medscape.com)
Bladder Cancer Treatment & Management: Approach Considerations, Treatment of Non-Muscle-Invasive Disease (Ta, T1, CIS),...
Bladder Cancer Treatment & Management: Approach Considerations, Treatment of Non-Muscle-Invasive Disease (Ta, T1, CIS),... (medscape.com)
Bladder Cancer Clinical Presentation: History, Physical Examination
Bladder Cancer Clinical Presentation: History, Physical Examination (medscape.com)
William Martin-Doyle, M.D. | Harvard Catalyst Profiles | Harvard Catalyst
William Martin-Doyle, M.D. | Harvard Catalyst Profiles | Harvard Catalyst (connects.catalyst.harvard.edu)
Medical Microbiology<...
Medical Microbiology<... (portal.research.lu.se)
DailyMed - GLATOPA- glatiramer acetate injection, solution
DailyMed - GLATOPA- glatiramer acetate injection, solution (dailymed.nlm.nih.gov)
These highlights do not include all the information needed to use GLATIRAMER ACETATE INJECTION safely and effectively. See...
These highlights do not include all the information needed to use GLATIRAMER ACETATE INJECTION safely and effectively. See... (dailymed.nlm.nih.gov)
These highlights do not include all the information needed to use GLATIRAMER ACETATE INJECTION safely and effectively. See...
These highlights do not include all the information needed to use GLATIRAMER ACETATE INJECTION safely and effectively. See... (dailymed.nlm.nih.gov)
These highlights do not include all the information needed to use GLATOPA® safely and effectively. See full prescribing...
These highlights do not include all the information needed to use GLATOPA® safely and effectively. See full prescribing... (dailymed.nlm.nih.gov)
These highlights do not include all the information needed to use COPAXONE® safely and effectively. See full prescribing...
These highlights do not include all the information needed to use COPAXONE® safely and effectively. See full prescribing... (dailymed.nlm.nih.gov)